Methods for better delivery of active agents to tumors
By using reversible permeability enhancers and controlled delivery technology on the skin surface, highly efficient targeted delivery of bioactive agents to solid tumors was achieved, solving the problem of insufficient accumulation of therapeutic agents in the tumor area in existing technologies, improving treatment efficacy and reducing toxicity to normal tissues.
Patent Information
- Application Number
- CN202411105255.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2015-07-24
- Filing Date
- 2016-07-22
- Publication Date
- 2024-11-08
AI Technical Summary
Existing technologies struggle to effectively target and deliver therapeutic agents to solid tumors, leading to drug resistance and cytotoxicity to normal cells. Furthermore, nanoparticles accumulate in non-target tissues during systemic circulation, resulting in low delivery efficiency.
By applying a reversible permeability enhancer to the skin surface, the permeability of epidermal barrier cells is increased, and bioactive agents are delivered directly to susceptible tumor areas at controlled flow rates and multiple depths, utilizing the lymphatic and vascular systems for targeted delivery.
It increased the concentration of the therapeutic agent in the tumor area, reduced toxicity to normal tissues, enhanced the therapeutic effect, and reduced drug resistance.
Smart Images

Figure CN118902979A_ABST
Abstract
Description
[0001] This application is a divisional application of an invention patent application with an application date of July 22, 2016, application number 201680042970.5, and invention name “Method for better delivery of active agents to tumors”.
[0002] Cross-references to related patent applications
[0003] This application claims priority to U.S. Provisional Patent Applications No. 62 / 196,570 and No. 62 / 196,578, both filed on July 24, 2015, which are both incorporated herein by reference in their entirety. Technical Field
[0004] The present invention relates to the delivery of pharmaceutical agents through the skin. Methods for delivering pharmaceutical agents, such as bioactive agents, are contemplated by the present invention. Specifically, methods for targeted delivery of pharmaceutical agents to one or more regions of the epidermis and thereby to one or more cancer tumors are described. Background Art
[0005] Cancer is the second leading cause of mortality in the United States, surpassed only by heart disease, with solid tumors accounting for more than 85% of cancer mortality. Currently, the standard of care treatment for patients presenting with solid tumors is invasive surgery followed by adjuvant chemotherapy and / or radiation therapy. While this strategy is sometimes successfully employed, it is accompanied by cytotoxicity to normal cells and tissues, in addition to the development of multidrug resistance (MDR).
[0006] Targeted cancer therapies offer the potential to improve the treatment of solid tumors. The idea is that by targeting therapeutics to solid tumors, cytotoxicity to normal cells and tissues can be minimized and potentially limit the emergence of drug resistance.
[0007] Currently explored targeted delivery methods include the use of intravenously (iv) administered nanoparticles (NPs) carrying drug payloads (such as micelles, liposomes, and dendrimers) for targeted delivery of therapeutic agents to solid tumors. Currently, systemic delivery of therapeutic agents to solid tumors via nanoparticles is a three-step process: (1) systemic delivery of therapeutic agents to different regions of the tumor; (2) transport of therapeutic agents across the vascular wall into the solid tumor (extravasation); and (3) diffusion of therapeutic agents from tumor tissue adjacent to blood vessels through the interstitial space to tumor cells.
[0008] Nanoparticles injected by iv must be retained in the systemic circulation for a sufficiently long time so that a portion of them extravasate and accumulate in solid tumor tissue. Due to the high permeability long retention (EPR) effect, nanoparticles can accumulate in solid tumors, Masumura et al., Cancer Research, (46), 6387-6392 (1986). The EPR effect is the result of the abnormal vasculature often associated with solid tumors. The vasculature of a tumor is usually characterized by blood vessels containing poorly arranged defective endothelial cells, which have large openings that usually lack smooth muscle and basement membranes. However, the degree of heterogeneity of the intratumoral vasculature, high tumor interstitial tissue fluid pressure, and tumor vasculature composition makes the consistency of delivery using these types of methods problematic.
[0009] Therefore, despite the EPR effect, these existing methods are severely limited because most of the nanoparticles (>95%) accumulate in other organs and tissues (e.g., liver, spleen, and lungs). Further considering this effect, there is evidence that larger nanoparticles accumulate more efficiently in tumors, but are subject to higher clearance rates from the blood circulation, see, e.g., Moghimim et al., Pharmacological Reviews, 2(53), 283-318 (2001).
[0010] An additional approach is to exploit specific ligand / receptor interactions to actively target drug or drug carrier nanoparticles or modifications to increase plasma half-life, thereby increasing the chance of an EPR effect. For example, PEGylated drug carriers have been shown to have increased systemic circulation retention. A modest increase in tumor delivery was observed, but still >90% of the delivered dose was cleared systemically within hours. Active targeting approaches can provide increased selectivity for drug release, but are similarly limited because they also rely on initial iv administration and subsequent extravasation of the drug or drug carrier, which can similarly lead to accumulation in distant tissues away from the tumor to be treated.
[0011] For example, two nanoparticle drug formulations have been approved by the FDA: (100 nm PEGylated liposomal form of doxorubicin) and (130 nm albumin-bound paclitaxel nanoparticles). Although these formulations exhibit some improved pharmacokinetic properties and reduced adverse effects, they provide only modest survival benefits. Therefore, the limited efficacy of these existing nanoparticle formulations may stem from their inability to effectively deliver therapeutic agents to solid tumors.
[0012] New methods for delivering increased concentrations of pharmaceutical agents to solid tumors are therefore highly desirable. Summary of the invention
[0013] One embodiment described herein is a method of delivering one or more agents to one or more susceptible tumors of a subject, the method comprising: (a) contacting one or more layers of the epidermis with one or more reversible permeation enhancers, wherein the one or more reversible permeation enhancers induce a reversible increase in the permeability of one or more barrier cells of the epidermis to at least one or more agents; (b) administering a total liquid dosage of the one or more agents in 2 to 50,000 sub-doses at a controlled application flow rate, wherein each sub-dose of the one or more agents is independently administered to multiple independent depths within the epidermis prior to any subsequent diffusion or movement of the one or more agents within the epidermis; and wherein after administration, the permeability of the one or more barrier cells is restored to a normal state prior to contacting the epidermis with the one or more permeation enhancers.
[0014] Another embodiment described herein is a method of treating a subject having a disease including one or more tumors by administering one or more bioactive agents to one or more tumors, the method comprising: (a) applying one or more delivery devices having 2 to 50,000 delivery structures to one or more sites of the skin including the vascular system and the lymphatic system, wherein the delivery device contacts one or more layers of the epidermis with one or more reversible permeation enhancers that induce a reversible increase in the permeability of one or more barrier cells of the epidermis to at least one or more bioactive agents; (b) administering a total liquid dosage of the one or more bioactive agents in 2 to 50,000 subdoses at a controlled administration flow rate through the delivery device, wherein one or more delivery structures are applied to the subject at one or more sites of the skin including the vascular system and the lymphatic system. The invention relates to a method of administering a bioactive agent to a plurality of tumors, wherein each sub-dose of the one or more bioactive agents is independently administered to a plurality of independent depths within the epidermis prior to any subsequent diffusion or migration of the one or more bioactive agents within the epidermis; wherein after the administering step, the one or more bioactive agents migrate or diffuse deeper through the epidermis to the basal layer of the epidermis and into at least a portion of the underlying viable dermis to achieve uptake of a portion of the one or more bioactive agents by one or more susceptible capillary plexuses or lymphatic capillary plexuses; wherein after administration and uptake, the one or more bioactive agents circulate to the one or more tumors via the vascular system or lymphatic system; and wherein a higher concentration of the one or more bioactive agents is delivered to the one or more tumors compared to intravenous, intradermal or subcutaneous delivery of the same one or more bioactive agents.
[0015] In some aspects of the embodiments described herein, the epidermis comprises a non-viable epidermis and a viable epidermis.
[0016] In some aspects of the embodiments described herein, the plurality of separate depths have a combined average depth of administration within the epidermis, wherein each separately administered sub-dose is at a depth that is a deeper depth, a shallower depth, or the same depth within the epidermis.
[0017] In some aspects of the embodiments described herein, applying a total liquid dosage of one or more agents to multiple depths within the epidermis comprises applying to a depth within at least a portion of the non-viable epidermis and / or at least a portion of the viable epidermis.
[0018] In some aspects of the embodiments described herein, the plurality of depths within the epidermis is from about 1 μm to about 500 μm beyond the superficialmost surface layer of the epidermis of the subject.
[0019] In some aspects of the embodiments described herein, a total liquid dosage of one or more agents is applied to a plurality of depths within the epidermis that consists only of one or more viable epidermal layers and no non-viable epidermal layers.
[0020] In some aspects of the embodiments described herein, the plurality of depths within the viable epidermis is from about 1 μm to about 250 μm beyond the deepest non-viable epidermis layer, but still within the viable epidermis.
[0021] In some aspects of the embodiments described herein, an average of the individual plurality of depths exhibits a combined average sub-dose delivery depth within the epidermis of about 70 μm to about 175 μm beyond the superficialmost surface layer of the epidermis.
[0022] In some aspects of the embodiments described herein, the frequency of each individual sub-dose application depth within the viable and / or non-viable epidermis exhibits a Gaussian distribution of depths.
[0023] In some aspects of the embodiments described herein, one or more pharmaceutical agents are administered by applying one or more delivery devices to one or more sites on the skin.
[0024] In some aspects of the embodiments described herein, the delivery device comprises an array comprising 2 to 50,000 delivery structures in fluid communication with one or more agents in a liquid carrier vehicle, wherein the delivery device comprises a mechanism for controlling the flow rate of administration; wherein the delivery structures comprise a mechanism for penetrating at least the superficial layer of the epidermis; and wherein the one or more agents in the liquid carrier vehicle are delivered by the delivery structures to multiple depths within the viable epidermis of the subject, thereby administering 2 to 50,000 sub-doses of the one or more agents.
[0025] In some aspects of the embodiments described herein, the delivery structure comprises a standard or non-standard geometry.
[0026] In some aspects of the embodiments described herein, the delivery structure comprises a needle.
[0027] In some aspects of the embodiments described herein, one or more pharmaceutical agents are administered at a controlled administration flow rate of about 0.01 μl / h to about 100 μl / h per delivery structure.
[0028] In some aspects of the embodiments described herein, the overall controlled application flow rate of one or more agents to multiple depths within the epidermis is about 0.02 μl / h / cm based on the total surface area of the delivery device in contact with the subject's skin. 2 to about 50,000 μl / h / cm 2 .
[0029] In some aspects of the embodiments described herein, the one or more agents are delivered to about 0.7 mm of the epidermis containing the one or more agents, prior to any subsequent diffusion or migration of the one or more agents within the epidermis. 3 To about 2,500mm 3 volume of tissue.
[0030] In some aspects of the embodiments described herein, one or more agents are administered continuously to the subject for a period of about 0.1 hours to about 96 hours.
[0031] In some aspects of the embodiments described herein, the one or more permeation enhancers are one or more chemical, physical, or electrical permeation enhancers.
[0032] In some aspects of the embodiments described herein, the physical penetration enhancer comprises a nanostructured or nanotopographic surface.
[0033] In some aspects of the embodiments described herein, a nanotopograhy surface is fabricated on the surface of a delivery structure as described herein.
[0034] In some aspects of the embodiments described herein, one or more agents applied to multiple depths within the skin migrate or diffuse deeper through the epidermis to the basal layer of the epidermis and into at least a portion of the underlying vital dermis.
[0035] In some aspects of the embodiments described herein, administration of one or more agents achieves a dermal interstitial fluid pressure in the underlying dermis of about 1 mmHg to about 15 mmHg.
[0036] In some aspects of the embodiments described herein, after delivery to the epidermis, one or more agents are absorbed by one or more tissues including one or more susceptible lymphatic capillary plexuses or one or more capillary plexuses.
[0037] In some aspects of the embodiments described herein, one or more agents circulate through one or more capillary plexuses and enter into or are within close proximity of one or more susceptible tumors.
[0038] In some aspects of the embodiments described herein, one or more agents circulate through one or more lymphatic capillary plexuses and enter into or are within close proximity of one or more susceptible tumors.
[0039] In some aspects of the embodiments described herein, the concentration of the one or more agents in the one or more susceptible tumors is about 1.25-fold to about 50-fold higher compared to intravenous, intradermal, or subcutaneous delivery of the same one or more agents.
[0040] In some aspects of the embodiments described herein, the serum absorption rate of one or more pharmaceutical agents is comparable to intradermal delivery and subcutaneous delivery of the same one or more pharmaceutical agents.
[0041] In some aspects of the embodiments described herein, the one or more pharmaceutical agents include a biologically active agent.
[0042] In some aspects of the embodiments described herein, the bioactive agent can be used to treat symptoms of a disease; slow the progression of the symptoms; delay the onset of the symptoms; prevent, ameliorate or alleviate the symptoms in a patient in need of treatment. BRIEF DESCRIPTION OF THE DRAWINGS
[0043] Figure 1 .Schematic diagram of the skin including the epidermis and dermis, illustrating the various tissues of the skin.
[0044] Figure 2 . Schematic diagram of the dermis illustrating the layers of the dermis.
[0045] Figure 3 . Exemplary delivery structures for administering active agents to the skin.
[0046] Figure 4 . Exemplary delivery structures with nanotopographic surfaces for administering active agents to the skin.
[0047] Figure 5 . Schematic diagram of the method used for delivery to the skin, illustrating the average depth of delivery.
[0048] Figure 6 .Optical coherence tomography (OCT) imaging of the skin after penetration of the skin with a needle array.
[0049] Figure 7. Modulation of tight junction proteins in Caco-2 epithelial cells by needles containing nanotopography.
[0050] Figure 8 Targeted delivery of an anticancer drug (trastuzumab) to tumors in vivo following delivery to rat skin.
[0051] Figures 9A and 9BRepresentative tumors after delivery of an anticancer drug (trastuzumab) to rat skin.
[0052] 10A and 10B. Distribution of delivered drugs to tumors grown in vitro using needle arrays or via drug-supplemented tissue culture medium.
[0053] Figures 10C and 10D. Effects of drug delivery methods on proliferation of tumor tissue cells grown in vitro following drug delivery using needle arrays or via drug-supplemented tissue culture medium.
[0054] Fig.11 . Imaging of a fluorescently labeled drug (Etanercept) applied to the skin, showing direct delivery to the lymphatic vasculature and lymph node tissue.
[0055] Fig.12 . Imaging of a fluorescently labeled drug (etanercept) applied to the skin, showing delivery to the axillary and mandibular lymph nodes.
[0056] Fig.13 . Biodistribution of etanercept following delivery to the skin using the methods of the present invention, demonstrating increased delivery to lymph nodes compared to traditional delivery methods.
[0057] Fig.14 . Serum absorption rate of drug (etanercept) after delivery to the skin, which shows that the serum absorption rate is similar to that of the traditional reference delivery method. DETAILED DESCRIPTION
[0058] There is a need for methods of controlled delivery of agents (e.g., bioactive agents) to solid cancer tumors in subjects. Accordingly, described herein are methods for controlled delivery of one or more agents to the skin followed by uptake of the one or more agents by the tumor. In some embodiments described herein, uptake of the one or more agents by the one or more tumors is facilitated by primary absorption by lymphatic tissue followed by delivery to the one or more susceptible tumors via the lymphatic vasculature.
[0059] As used herein, the term "vital skin" refers to the area of the skin immediately below the stratum corneum of the epidermis (including the dermis) but above the subcutaneous tissue layer. This term encompasses both the vital epidermis and the vital dermis. The actual depth of the vital skin will vary depending on the location of the skin, the age and physiology of a given subject. The term vital skin also describes that this portion of the skin includes nucleated living cells, usually mitotic. In some aspects described herein, the vital skin also contains at least one or more lymphatic capillary plexuses and / or one or more capillary plexuses.
[0060] As used herein, the term "vital dermis" refers to the area of the skin immediately below the basal layer of the epidermis but above the subcutaneous tissue layer. The viable dermis includes the papillary dermis and reticular dermis of the dermis, which further include, for example, blood capillaries and lymphatic capillaries, as well as other tissue types.
[0061] As used herein, the term "vital epidermis" refers to the area of the skin immediately below the stratum corneum. The viable epidermis includes the basal or germinal layer, the squamous cell layer or spinous layer, and the granular cell layer or granular layer.
[0062] As used herein, the term "agent" refers to a compound, substance, composition or molecule to be delivered. Illustrative and non-limiting examples include bioactive agents, nucleic acids (such as microRNAs), dyes (such as contrast agents and fluorescent reporters), vaccines, etc.
[0063] As used herein, the term "bioactive agent" refers to any biocompatible agent that triggers a cellular response. The term bioactive agent includes any drug, active ingredient, active drug substance, or vaccine. For example, the bioactive agent described in the embodiments herein may include drugs (such as small molecule drugs, biosimilar drugs, biologics, etc.), nanoparticles, lipids, liposomes, proteins (e.g., recombinant proteins, antibodies, etc.), and the like.
[0064] As used herein, the terms "drug", "active ingredient", "active drug substance" or "active pharmaceutical agent" refer to an active ingredient, compound or substance, composition or mixture thereof that provides a pharmacological effect (usually a beneficial one). References to a specific active ingredient include the active ingredient (where appropriate) and any pharmaceutically acceptable salt or ester thereof.
[0065] The term "amount" or "dose" refers to any form of preparation containing an amount of active ingredient sufficient to produce a therapeutic effect by a single administration.
[0066] As used herein, the term "titration" refers to the incremental increase in the amount of a drug or the rate of administration to a level that provides the optimal therapeutic effect.
[0067] As used herein, the term "controlled delivery" refers to a method of administration that produces controlled delivery of one or more agents over a desired period of time. As used herein, it encompasses the terms "improved delivery," "sustained delivery," "extended delivery," and "delayed delivery." In some aspects described herein, the method for controlled delivery results in delivery of one or more agents or active drug substances that achieves a therapeutic threshold for the longest period of time.
[0068] As used herein, the term "delayed delivery" refers to the delivery of one or more agents according to a desired profile over an extended period of time under physiological conditions or in an in vitro test. By "extended period of time" is meant at least about 20 minutes; about 30 minutes; about 1 hour; about 2 hours; about 4 hours; about 6 hours; about 8 hours; about 10 hours; about 12 hours; about 14 hours; about 16 hours; about 18 hours; about 20 hours; about 24 hours; or even longer continuous periods of time.
[0069] As used herein, the term "improved delivery" refers to delivery of one or more pharmaceutical agents at a slower rate than an immediate delivery formulation under physiological conditions or in in vitro testing.
[0070] As used herein, the term "sustained delivery" refers to the delivery of one or more pharmaceutical agents over an extended period of time, such as minutes, hours, or days, such that less than all of the active ingredient is initially released. A sustained release rate can, for example, provide delivery of a specific amount of one or more pharmaceutical agents or active drug substances over a period of time under physiological conditions or in vitro testing.
[0071] As used herein, the term "extended delivery" refers to the delivery of one or more agents over an extended period of time, such as at least about 20 minutes; about 30 minutes; about 1 hour; about 2 hours; about 4 hours; about 6 hours; about 8 hours; about 10 hours; about 12 hours; about 14 hours; about 16 hours; about 18 hours; about 20 hours; about 24 hours; about 48 hours; about 72 hours; or even longer.
[0072] The term "initial delivery" or "initial delivery" refers to the tissue location that an agent first contacts. In some aspects described herein, initial delivery can refer to the location within the skin (e.g., non-viable epidermis, viable epidermis, or viable dermis) that one or more agents first contact after being delivered by a delivery device or one or more delivery structures of a delivery device.
[0073] As used herein, "conventional delivery" means any method used in the art prior to the present invention for delivering one or more biodynamically or actively active substances similar to intravenous (iv), iontophoretic, subcutaneous (sc), intramuscular (im) or intradermal (id) injections or topical formulations. Exemplary methods include subcutaneous, iontophoretic and intradermal delivery methods, such as those described in US 5800420, US20050180952, Xie et al., Expert Opin Drug Deliv., 6(8), 785-792 (2009) and Zhang and Wei-Yue., Cancer Biol Med., (11), 247-254 (2014), each of which is incorporated herein by reference for its general description of conventional delivery methods.
[0074] The term "targeted drug delivery" refers to the location where the drug accumulates primarily. This term is separate and distinct from commonly used terms such as "targeted therapy," which more specifically refers to specific interactions with cell or tissue types (e.g., ligand / receptor interactions).
[0075] The term "BCS Class I, Class II, Class III, or Class IV" refers to whether a compound or active drug substance has high or low permeability and whether it has high or low solubility (e.g., poorly soluble). BCS Class I drugs have high permeability and high solubility; BCS Class II drugs have high permeability and low solubility; BCS Class III drugs have low permeability and high solubility; and BCS Class IV drugs have low permeability and low solubility. An immediate-release drug substance is considered highly soluble when the highest dose strength is soluble in 250 mL or less of aqueous medium at 37±1°C over a pH range of 1 to 7.5. A sufficient number of pH conditions should be evaluated to precisely define the pH-solubility distribution. An immediate-release drug substance is considered highly permeable when the extent of absorption in humans is determined to be 90% or more of the administered dose based on a mass balance assay or compared to an intravenous reference dose, in the absence of evidence of instability in the gastrointestinal tract. Permeability can be determined using mass balance, absolute bioavailability, or intestinal perfusion methods. When a single method cannot conclusively demonstrate the permeability classification, two different methods are desirable. A drug product is considered to be rapidly dissolving when not less than 85% of the labeled amount of the drug substance dissolves in 30 minutes in each of the following media in a volume of 900 ml or less using USP Apparatus I at 100 rpm (or Apparatus II at 50 rpm): (1) enzyme-free 0.1 N HCl or artificial gastric fluid USP; (2) pH 4.5 buffer; and (3) enzyme-free pH 6.8 buffer or artificial intestinal fluid USP. See FDA Guidance for Industry: Waiver of InVivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. (August 2000), which is incorporated herein by reference for such teachings.
[0076] As used herein, "bioavailability" means the total amount of a given amount of an administered agent that reaches the blood compartment. This is usually measured as the area under the curve of a plot of concentration versus time.
[0077] As used herein, "tissue" refers to a group or layer of cells that perform a function together, including but not limited to skin tissue, lymphatic tissue (e.g., lymph nodes), mucosal tissue, reproductive tissue, cervical tissue, vaginal tissue, and any body part composed of different types of tissue and performing a specific function, i.e., an organ, including but not limited to the lungs, spleen, colon, thymus. As used herein, tissue includes any tissue that interacts with or is susceptible to the environment, such as skin or mucosal tissue.
[0078] As used herein, "tissue bioavailability" means the amount of drug biologically available in a specific tissue in vivo. These amounts are usually measured as activities related to other measurable characteristics that can be used for diagnosis and / or therapy, such as binding, labeling, detection, transport, stability, biological action, or other measurable characteristics that can be used for diagnosis and / or therapy. In addition, it should be understood that the definition of "tissue-bioavailability" also includes the amount of the drug that can be used in a specific tissue. "Tissue-bioavailability" includes the total amount of the drug accumulated in a specific tissue, the amount of the drug presented to a specific tissue, the amount of the drug accumulated per mass / volume of a specific tissue, and the amount of the drug accumulated per unit time in a specific tissue of a specific mass / volume. Tissue bioavailability includes the amount of drug available in a specific tissue or tissue collection, such as tissues that constitute the vascular system and / or various organs of the body (for example, a body part composed of different types of tissues and performing a specific function).
[0079] As used herein, the term “C max ” means the maximum observed blood (plasma, serum or whole blood) concentration or the maximum blood concentration calculated or estimated from the concentration versus time curve and is expressed in mg / L or ng / mL, as appropriate.
[0080] As used herein, the term “C min ” means the minimum observed blood (plasma, serum or whole blood) concentration or the minimum blood concentration calculated or estimated from the concentration versus time curve and is expressed in mg / L or ng / mL, as appropriate.
[0081] As used herein, the term “C avg ” refers to the blood (plasma, serum or whole blood) concentration of the drug during the dosing interval, calculated as AUC / dosing interval and expressed in mg / L or ng / mL, as appropriate.
[0082] As used herein, the term “ max ” refers to the C max The time at which the event occurred, expressed in hours (h) or minutes (min), as appropriate.
[0083] As used herein, the term "AUC 0”→τRefers to the area under the blood (plasma, serum or whole blood) concentration versus time curve from time zero to time tau (τ) during the dosing interval at steady state, where tau is the length of the dosing interval and is expressed in units of hmg / L or hng / mL, if applicable. For example, as used herein, the term AUC 0→12 It is the area under the concentration versus time curve from 0 to 12 hours.
[0084] As used herein, the term "AUC 0”→∞ It is the area under the blood (plasma, serum or whole blood) concentration versus time curve from time 0 hours to infinity and is expressed in units of h mg / L or h ng / mL, as appropriate.
[0085] As used herein, the term "AUC 总体 Refers to the combined area under the blood (plasma, serum or whole blood) versus time curve for at least one or more doses of a pharmaceutical composition described herein, and is expressed in units of h mg / L (or h ng / mL). In one aspect, "AUC 总体 ” refers to the combined area under the blood concentration versus time curve for at least two doses of a pharmaceutical composition described herein.
[0086] The term "treat" refers to administering therapy in an amount, manner or pattern effective to improve the signs, symptoms or parameters associated with a disorder.
[0087] The term "prophylaxis" refers to preventing or reducing the progression of a disorder to a statistically significant degree or to an extent detectable by one skilled in the art.
[0088] As used herein, the term "substantially" means to a great or significant degree, but not completely. In some aspects, in the various embodiments described herein, substantially means 90% to 99% or more, including every integer in the specified range.
[0089] As used herein, the terms "subject" and "patient" are used interchangeably. As used herein, the subject is preferably a mammal, such as a non-primate (e.g., cow, pig, horse, cat, dog, rat, etc.) and a primate (e.g., monkey and human), most preferably a human.
[0090] As used herein, the terms "disorder" and "disease" are used interchangeably to refer to a condition in a subject. A disease includes any interruption, cessation or disorder of a body function, system or organ.
[0091] As used herein, the term "treatment" refers to eradication, alleviation or amelioration of the symptoms of a disease or condition. In some embodiments, treatment refers to eradication, removal, alteration or control of primary, regional or metastatic cancer tissue caused by the administration of one or more therapeutic agents. In certain embodiments, such terms refer to minimizing or delaying the spread of such disease by administering one or more therapeutic agents to a subject suffering from cancer.
[0092] As used herein, the term "management" refers to the beneficial effects that a subject obtains from administering a prophylactic or therapeutic agent that does not result in a cure of the disease. In certain embodiments, one or more prophylactic or therapeutic agents are administered to a subject to "manage" the disease, thereby preventing the progression or worsening of the disease.
[0093] As used herein, the terms "prevent", "preventing" and "prevention" refer to preventing the recurrence or onset of one or more symptoms of a disorder in a subject by administering a prophylactic or therapeutic agent.
[0094] As used herein, the phrase "adverse effect" covers the undesirable and undesirable effects of preventive or therapeutic agents. Adverse effects are always undesirable, but undesirable effects are not necessarily undesirable. The adverse effects of preventive or therapeutic agents may be harmful, uncomfortable or risky. Adverse effects from chemotherapy include but are not limited to gastrointestinal toxicity, such as but not limited to diarrhea and flatulence formed in early and late stages, nausea, vomiting, anorexia, leukopenia, anemia, neutropenia, weakness, abdominal cramps, fever, pain, weight loss, dehydration, alopecia, dyspnea, insomnia, dizziness, mucositis, dry mouth and renal failure and constipation, nerve and muscle effects, temporary or permanent damage to kidney and bladder, flu-like symptoms, fluid retention and temporary or permanent infertility. Adverse effects from radiotherapy include but are not limited to fatigue, dry mouth and loss of appetite. Adverse effects from biological therapy / immunotherapy include but are not limited to rash or swelling at the site of application, flu-like symptoms such as fever, chills and fatigue, digestive tract problems and allergic reactions. Adverse effects from hormonal therapy include, but are not limited to, nausea, fertility problems, depression, loss of appetite, eye problems, headaches, and weight fluctuations. Additional undesirable effects commonly experienced by patients are numerous and known in the art, see, e.g., Physicians' Desk Reference (69th Edition, 2015), which is incorporated herein by reference in its entirety.
[0095] As used herein, the phrase "delivery to susceptible tissue" or "viable tissue" refers to the delivery of one or more agents to living tissues or tissue structures, such as skin, spleen, thymus, lungs, vasculature, lymphatic system, lymph nodes, heart and brain, etc. In some embodiments described herein, the methods, compositions and devices further described herein can adjust the structure of living tissues or tissue structures to promote the absorption of one or more agents. In some aspects, living tissues or tissue structures include skin and individual viable cells that constitute the skin. In some aspects described herein, the delivery method induces specific cells or tissues (e.g., viable skin) to be susceptible to the delivery of one or more agents to the specific tissue. In some aspects described herein, the living tissue or tissue structure includes one or more layers of viable skin, such as the viable layer of the epidermis and the underlying dermis. In some aspects described herein, the living tissue or tissue structure includes lymphatic capillaries, such as delivery to susceptible lymphatic capillary plexuses.
[0096] Described herein are methods and devices for delivering an agent initially to the skin, and subsequently to a susceptible tumor. In certain embodiments described herein are methods for delivering an agent to the lymphatic vasculature and to a susceptible tumor.
[0097] In some embodiments described herein are methods for delivering one or more agents to the skin. In some aspects, one or more agents are delivered to at least a portion or region of viable skin or non-viable skin. In some aspects, one or more agents are delivered to at least a portion or region of viable epidermis. In some aspects, one or more agents are delivered to at least a portion or region of non-viable epidermis. As further described herein, one or more agents are able to pass through the viable epidermis and enter the dermis, thereby approaching one or more capillaries or lymphatic capillaries. In some embodiments described herein, delivery of one or more agents to the skin results in uptake of one or more agents by susceptible tumors. Delivery to tumors may be due to absorption through lymphatic capillaries or capillaries or both, as further described herein.
[0098] Based on the barrier providing function of the skin, there are several difficulties in delivering to the skin. Anatomically, the skin is broadly composed of two major tissue layers, the outer epidermis and the lower dermis, which together constitute the skin. The skin system in a broader sense includes skin, hair, nails, exocrine glands and subcutaneous tissue. Due to this barrier function, many transdermal or microneedle methods for delivering to the skin and passing through the epidermis and entering the viable dermis are unsuccessful, resulting in the material delivered being retained in one or more layers of the epidermis.
[0099] The epidermis is subdivided into four main layers. From bottom to top, in order, there are the basement membrane, the basal layer or the germinal layer, the squamous cell layer or the spinous layer, the granular cell layer or the granular layer, and the stratum corneum or the stratum corneum. Of these, the three layers, the lower three layers (i.e., the germinal layer, the spinous layer, and the granular layer), constitute the living layers of the epidermis.
[0100] These living layers of the epidermis are important for the barrier function of the skin, and the skin depends on the self-renewal and differentiation of the stem cells located at the base to regenerate the upper layer of the skin and provide enucleated cells for the barrier layer or stratum corneum. The barrier function of the epidermis is largely due to the tight junctions (tight junctions) that prevent macromolecules (such as proteins), microorganisms and other potential toxic chemicals from passing through. Therefore, these tight junctions are barrier structures, which include transmembrane protein networks and multiple plaque proteins (such as ZO-1, ZO-2, ZO-3, cingulate proteins, symplekins) embedded in adjacent plasma membranes (such as, tight junction proteins (claudin), occludens and junction adhesion molecules). Tight junctions are present in almost all types of tissues, including the entire viable epidermis of internal epithelium (such as intestinal epithelium, blood-brain barrier, blood vessels, lymphatic vessels) and skin.
[0101] The thickness of the skin varies according to location and age. For example, the eyelids have one of the thinnest epidermal layers, less than about 0.2 mm; the palms and soles of the feet have some of the thickest epidermal layers, measuring close to 1.5 mm. The thickness of the dermis also varies according to the location of the tissue, with the dermis of the back being 30-40 times thicker than the epidermis, see William D. James, Timothy Berger, and Dirk Elston., Clinical Dermatology (11th ed. 2011), which is incorporated herein by reference in its entirety.
[0102] Under the epidermis is the dermis, which comprises two layers, the outermost part called the papillary dermis and the deeper layer called the reticular dermis. The papillary dermis contains a large amount of microcirculatory blood and lymphatic plexus. In contrast, the reticular dermis is relatively acellular and is composed of dense collagen and elastic connective tissue. Below the epidermis and dermis is the subcutaneous tissue, also known as the hypodermis, which is composed of connective tissue and adipose tissue. See, Physiology, Biochemistry, and Molecular Biology of the Skin, Second Edition, (L. A. Goldsmith, ed., 2nd Edition Oxford University Press, New York, 1991), which is incorporated herein by reference in its entirety.
[0103] Some embodiments described herein are methods for targeted delivery of one or more agents to one or more tumors. The delivery of one or more agents to one or more tumors is promoted by delivering one or more agents to the skin at a certain rate and depth, as further described herein. The delivery of one or more agents targeting one or more tumors can be promoted by delivery to one or more susceptible capillary lymphatic plexuses. In some other aspects, the delivery of one or more agents targeting one or more tumors can be promoted by delivery to one or more susceptible capillary plexuses. In some aspects, the tumor can be a primary tumor or a secondary tumor (e.g., a metastasis of a primary tumor).
[0104] In some embodiments described herein, one or more agents are delivered to a location within the skin, wherein after initial administration, the one or more agents move or diffuse to a location close to the vascular system and lymphatic system. As described herein, such placement within the skin may result in delivery of the agent to the lymphatic capillary bed (or lymphatic drainage bed or lymphatic capillary plexus), which physiologically serves to drain interstitial fluid at a given location to the rest of the lymphatic system.
[0105] In some embodiments described herein, one or more medicaments are directly delivered to a certain position in the epidermis. In some aspects, one or more medicaments diffuse, move, flow or migrate to a position close to the lymphatic system. As described herein, after the method described herein, this arrangement in the epidermis causes the medicament to diffuse or move through the epidermis and into the viable epidermis, thereby allowing the medicament to directly contact the capillary lymphatic bed (or referred to as the lymphatic drainage bed or the capillary lymphatic plexus) present in the shallowest layer, which is physiologically used as the interstitial fluid of a given position is drained to the remainder of the lymphatic system. In some other aspects, this arrangement in the skin may cause the medicament to be locally delivered to the capillary bed. The method for delivering one or more medicaments to the capillary lymphatic bed described herein may further result in the medicament being delivered to the first lymph node (also referred to as "primary" lymph node) of the drainage capillary lymphatic bed. In some aspects, the local delivery of one or more medicaments may also result in the medicament being delivered to the other lymph nodes (also referred to as "secondary" lymph nodes) downstream of the primary lymph node. In some aspects, the agent may eventually enter the bloodstream and be delivered systemically.In some aspects described herein, delivering one or more agents to the skin results in targeted delivery of the one or more agents to one or more susceptible tumors in the subject.
[0106] In some embodiments described herein, it is a method for delivering one or more agents to a series of depths in the skin. In some aspects, one or more agents are delivered to the epidermis, and the epidermis includes a non-viable epidermis (e.g., stratum corneum) and a viable epidermis located under the non-viable epidermis. As described herein, the depth in the skin can vary according to the position, age, and physiology of the skin of a given subject. The overall depth of delivery of one or more agents in the skin can be described as the distribution of multiple depths at which one or more agents may be located after the initial application of one or more agents using the methods described herein. The total distribution of the delivery depth of one or more active agents depends on the depth of application rate, volume, and delivery structure in the skin, as further described herein. Therefore, the portion of the total delivery agent can be at a shallower depth or a deeper depth, wherein the total delivery agent has an average delivery depth and standard deviation of a series of delivery depths. Therefore, in some aspects, as described herein, one or more agents are delivered to the skin and can conform to a simple normal distribution (i.e., Gaussian distribution) in the skin. In some other aspects, one or more agents are delivered to the skin and can conform to a multimodal distribution of depth in the skin.
[0107] As further described herein, one or more medicaments are delivered to the epidermis, wherein the one or more medicaments administered show a depth distribution in the epidermis, providing an increased lymphatic uptake of one or more medicaments. The delivery method described herein realizes the previously unrealized aspect of contacting the potential dermal capillaries of all levels. The method described herein also includes reversibly increasing the porosity of the barrier function of the skin to promote the diffusion of the medicament downward (top to bottom) or moving through all layers of the epidermis and into the viable dermis. In some aspects described herein, compared with alternative parenteral delivery methods (such as direct intradermal delivery technology), delivery to the epidermis produces greater lymphatic uptake, and the alternative parenteral delivery method may miss the initial capillaries just below the epidermal basement membrane, resulting in reduced lymphatic uptake. Without being bound by any theory, the reason for this situation is that the medicament can move more freely downward through the reticular dermis and enter the subcutaneous tissue. Thus, by providing methods as described herein that allow diffusion or movement of an agent through the epidermis at multiple flow rates, superficial and deeper lymphatic vessels within the dermis can be contacted with the agent, which increases the rate or amount of absorption of the agent by one or more susceptible lymphatic capillaries.
[0108] In some embodiments described herein, at least a portion or all of one or more medicaments can be delivered or applied directly to the initial depth in the skin including the non-viable epidermis and / or the viable epidermis. In some aspects, in addition to the epidermis, a portion of one or more medicaments can also be delivered directly to the viable dermis. The range of delivery depth will depend on the disease being treated and the skin physiology of a given subject. The initial delivery depth can be defined as a certain position in the skin, where the medicament applied first contacts as described herein. Without being bound by any theory, it is believed that the one or more medicaments applied can move (e.g., diffuse) from the initial delivery site (e.g., non-viable epidermis, viable epidermis, or viable dermis) to a deeper position in the viable skin. For example, a portion or all of the applied medicament can be delivered to the non-viable epidermis, and then continue to move (e.g., diffuse) into the viable epidermis, and pass through the basal layer of the viable epidermis and enter the viable dermis. Alternatively, a portion or all of the administered agent may be delivered to the viable epidermis (i.e., immediately below the stratum corneum), and then continue to move (e.g., diffuse) through the basal layer of the viable epidermis and into the viable dermis. Finally, a portion or all of the administered agent may be delivered to the viable dermis. The movement of one or more active agents throughout the skin is multifactorial and depends, for example, on the liquid carrier composition (e.g., its viscosity), the rate of application, the delivery structure, etc. This movement through the epidermis and into the dermis can be further defined as a transport phenomenon and quantified by mass transfer rate and / or fluid mechanics (e.g., mass flow rate).
[0109] Thus, in some embodiments described herein, one or more agents can be delivered to a depth in the epidermis where the one or more agents move through the basal layer of the viable epidermis and into the viable dermis. In some aspects described herein, the one or more agents are then absorbed by one or more susceptible lymphatic capillary plexuses or capillaries and then delivered to one or more susceptible tumors.
[0110] In some embodiments described herein, one or more medicaments can be delivered in a liquid carrier solution. On the one hand, the tension of the liquid carrier can be hypertonic for the fluid in the capillary or lymphatic capillary. On the other hand, the tension of the liquid carrier solution can be hypertonic for the fluid in the capillary or lymphatic capillary. On the other hand, the tension of the liquid carrier solution can be isotonic for the fluid in the capillary or lymphatic capillary. The liquid carrier solution may also include at least one or more pharmaceutically acceptable excipients, diluents, cosolvents, microparticles or colloids. Pharmaceutically acceptable excipients used in liquid carrier solutions are known, see, for example, Pharmaceutics: Basic Principles and Application to Pharmacy Practice (Alekha Dash et al., 1st edition 2013), incorporated herein by reference for teachings herein.
[0111] In some embodiments, the one or more agents can then be delivered directly or indirectly to the one or more susceptible tumors by first delivering the one or more agents to a depth in the skin, resulting in delivery to a susceptible lymphatic capillary plexus or a capillary plexus as described herein. In one aspect, targeted delivery of the one or more agents to the one or more susceptible tumors comprises delivery to the epidermis, wherein the one or more agents are absorbed by the susceptible lymphatic capillary plexus prior to being absorbed by the one or more susceptible tumors. In another aspect, targeted delivery of the one or more agents to the one or more susceptible tumors comprises delivery to the viable epidermis and / or the viable dermis, wherein the one or more agents are absorbed by the capillary plexus prior to being absorbed by the one or more susceptible tumors.
[0112] In some embodiments described herein, the depth distribution in the skin (in which a portion of the one or more agents is initially delivered) that results in uptake of one or more agents by one or more susceptible tumors ranges from about 5 μm to about 4,500 μm, including each integer in the specified range. In some aspects, the depth in the skin for initial delivery of one or more agents ranges from about 5 μm to about 2,000 μm, including each integer in the specified range. In some aspects, the depth in the skin for initial delivery of one or more agents ranges from about 5 μm to about 1,000 μm, including each integer in the specified range. In some aspects, the depth in the skin for initial delivery of one or more agents ranges from about 5 μm to about 500 μm, including each integer in the specified range. In some aspects, the depth in the skin for initial delivery of one or more agents ranges from about 5 μm to about 250 μm, including each integer in the specified range. In some aspects, the depth in the skin for initial delivery of one or more agents ranges from about 5 μm to about 100 μm, including each integer in the specified range. In some aspects, the average depth in the skin for initial delivery of one or more agents is about 5 μm, about 10 μm, about 20 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm, about 90 μm, about 100 μm, about 125 μm, about 150 μm, about 175 μm, about 200 μm, about 225 μm, about 250 μm, about 275 μm, about 300 μm, about 350 μm, about 400 μm, about 450 μm, about 500 μm, about 550 μm, about 600 μm, about 650 μm, about 700 μm, about 750 μm, about μm, about 800μm, about 850μm, about 900μm, about 950μm, about 1,000μm, about 1,100μm, about 1,200μm, about 1,300μm, about 1,400μm, about 1,500μm, about 1,600μm, about 1,700μm, about 1,800μm, about 1,900μm, about 2,000μm, about 2,250μm, about 2,500μm, about 2,750μm, about 3,000μm, about 3,250μm, about 3,500μm, about 3,750μm, about 4,000μm to about 4,500μm.
[0113] In some embodiments described herein, one or more agents are delivered to the viable skin, wherein the depth distribution in the viable skin for delivering one or more agents is just beyond the stratum corneum of the epidermis but above the subcutaneous tissue, which results in the uptake of one or more agents by one or more susceptible tumors. Whether the agent is in the epidermis or the dermis will depend on the thickness of the epidermis, for example, it is expected that a shallower delivery depth of about 1 μm to about 250 μm, including about 1 μm to about 250 μm above the stratum corneum, will be in the viable epidermis. It is expected that a depth greater than 400 μm, 500 μm or 700 μm is likely to be at least in the shallowest part of the viable dermis (e.g., papillary dermis). In some aspects, the depth range in the viable skin for delivering one or more agents is about 1 μm to about 5,000 μm above the stratum corneum, but still located in the viable skin above the subcutaneous tissue, including each integer in the specified range. In some aspects, the depth in the viable skin for delivery of one or more agents ranges from about 1 μm above the stratum corneum to about 3,500 μm, but still within the viable skin above the subcutaneous tissue, including each integer in the specified range. In some aspects, the depth in the viable skin for delivery of one or more agents ranges from about 1 μm above the stratum corneum to about 2,000 μm, but still within the viable skin above the subcutaneous tissue, including each integer in the specified range. In some aspects, the depth in the viable skin for delivery of one or more agents ranges from about 1 μm above the stratum corneum to about 1,000 μm, but still within the viable skin above the subcutaneous tissue, including each integer in the specified range. In some aspects, the depth in the viable skin for delivery of one or more agents ranges from about 1 μm above the stratum corneum to about 500 μm, but still within the viable skin above the subcutaneous tissue, including each integer in the specified range. In some aspects, the depth in the viable skin for delivery of one or more agents ranges from about 1 μm to about 250 μm above the stratum corneum, but still within the viable skin above the subcutaneous tissue, including each integer in the specified range. In some aspects, the depth in the viable skin for delivery of one or more agents ranges from about 1 μm to about 100 μm above the stratum corneum, but still within the viable skin above the subcutaneous tissue, including each integer in the specified range. In some aspects, the depth in the viable skin for delivery of one or more agents ranges from about 1 μm to about 50 μm above the stratum corneum, but still within the viable skin above the subcutaneous tissue, including each integer in the specified range.In some aspects, the average depth in the viable skin for delivery of one or more agents is about 1 μm, about 5 μm, about 10 μm, about 20 μm, about 30 μm, about 40 μm, about 50 μm, about 60 μm, about 70 μm, about 80 μm, about 90 μm, about 100 μm, about 150 μm, about 250 μm, about 350 μm, about 450 μm, about 550 μm, about 650 μm, about 750 μm, about 850 μm, about 950 μm, about 1,000 μm, about 1,100 μm, about 1,200 μm, about 1,300 μm, about 1,400 μm, about 1,500 μm, about 1,600 μm, about 1,700 μm, about 1,800 μm, about 1,900 μm, about 2,000 μm, about 2,250 μm, about 2,500 μm, about 2,750 μm, about 3,000 μm, about 3,250 μm, about 3,500 μm, about 3,750 μm, about 4,000 μm, about 4,500 μm or about 5,000 μm, but still within the viable skin above the subcutaneous tissue.
[0114] Non-limiting tests for assessing the initial delivery depth in the skin can be invasive (e.g., biopsy) or non-invasive (e.g., imaging). Conventional non-invasive optical methods can be used to assess the delivery depth of the agent into the skin, including optical irradiance spectroscopy, fluorescence spectroscopy, photothermal spectroscopy, or optical coherence tomography (OCT). Methods using imaging can be performed in real time to assess the initial delivery depth. Alternatively, an invasive skin biopsy can be taken immediately after the agent is administered, followed by standard histology and staining methods to determine the delivery depth of the agent. For examples of optical imaging methods that can be used to determine the skin penetration depth of an administered agent, see Sennhen et al., Skin Pharmacol., 6(2), 152-160 (1993), Gotter et al., Skin Pharmacol. Physiol., 21, 156-165 (2008), and Mogensen et al., Semin. Cutan. Med. Surg., 28, 196-202 (2009), each of which is incorporated herein by reference for its teachings herein.
[0115] In some embodiments described herein, it is a method for the extended delivery (or administration) of one or more medicaments described herein. In some aspects, one or more medicaments are delivered in a time period of about 0.5 hour to about 72 hours (including each time integer in the specified range). In some aspects, one or more medicaments are delivered in a time period of about 0.5 hour to about 48 hours (including each time integer in the specified range). In some aspects, one or more medicaments are delivered in a time period of about 0.5 hour to about 24 hours (including each time integer in the specified range). In some aspects, one or more medicaments are delivered in a time period of about 0.5 hour to about 12 hours (including each time integer in the specified range). In some aspects, one or more medicaments are delivered in a time period of about 0.5 hour to about 6 hours (including each time integer in the specified range). In some aspects, one or more agents are delivered within a period of about 0.5 hours, about 1 hour, about 1.5 hours, about 2 hours, about 2.5 hours, about 3 hours, about 3.5 hours, about 4 hours, about 4.5 hours, about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 16 hours, about 20 hours, about 24 hours, about 28 hours, about 32 hours, about 36 hours, about 40 hours, about 44 hours, about 48 hours, about 52 hours, about 56 hours, about 60 hours, about 64 hours, about 68 hours, or about 72 hours.
[0116] In some embodiments described herein, one or more agents in a liquid carrier solution are applied to an initial approximate space in the skin. The one or more agents in the liquid carrier solution initially delivered to the skin (e.g., before any subsequent movement or diffusion) can be distributed within or contained by the approximate three-dimensional volume of the skin. Thus, as further described herein, the one or more initially delivered agents exhibit a Gaussian distribution of delivery depth and will also have a Gaussian distribution within the three-dimensional volume of skin tissue. In some aspects, the one or more agents in the liquid carrier solution can be applied to the skin, wherein the tissue volume of the one or more agents contained in the liquid carrier solution is about 0.7 mm 3 To about 2,500mm 3 , including each integer within the specified range. In some aspects, one or more agents in a liquid carrier solution can be applied to the skin, wherein the total three-dimensional surface area of the applied liquid carrier solution containing the one or more agents is about 18 mm 2 To about 20,000mm 2 , including each integer within the specified range. In some aspects, one or more pharmaceutical agents in a liquid carrier solution can be applied to the skin, wherein the liquid carrier solution containing the one or more pharmaceutical agents has a three-dimensional surface area to volume ratio of about 35 mm-1 To about 5mm -1 , including every integer within the specified range. The exemplified volumes, surface areas, and surface area to volume ratios can vary depending on the local physiological administration site, the size of the delivery device, the depth of delivery, and the disease to be treated.
[0117] The tissue volume, surface area, and surface area to volume ratio of the delivered agent can be determined by using standard geometric calculations after measuring the overall dimensions (width and length) of the delivery device in contact with the subject's skin and measuring the deepest delivery depth of the initial application of the agent using standard methods and techniques for measuring delivery depth as described herein.
[0118] In some embodiments described herein, multiple dosages of one or more medicaments in a liquid carrier solution as described herein are simultaneously applied to the skin for targeted delivery to one or more susceptible tumors. In some aspects, one or more medicaments in a liquid carrier solution are simultaneously applied with 2 to 50,000 (including each integer in the specified range) subdoses. In some aspects, one or more medicaments in a liquid carrier solution are simultaneously applied with 2 to 25,000 subdoses. In some aspects, one or more medicaments in a liquid carrier solution are simultaneously applied with 2 to 15,000 (including each integer in the specified range) subdoses. In some aspects, one or more medicaments in a liquid carrier solution are simultaneously applied with 2 to 10,000 (including each integer in the specified range) subdoses. In some aspects, one or more medicaments in a liquid carrier solution are simultaneously applied with 2 to 5,000 (including each integer in the specified range) subdoses. In some aspects, one or more medicaments in a liquid carrier solution are simultaneously applied with 2 to 1,000 (including each integer in the specified range) subdoses. In some aspects, one or more medicaments in 10 liquid carrier solutions are administered simultaneously with 2 to 500 (each integer included in the specified range) subdoses. In some aspects, one or more medicaments in a liquid carrier solution are administered simultaneously with 2 to 250 (each integer included in the specified range) subdoses. In some aspects, one or more medicaments in a liquid carrier solution are administered simultaneously with 2 to 150 (each integer included in the specified range) subdoses. In some aspects, one or more medicaments in a liquid carrier solution are administered simultaneously with 2 to 100 subdoses. In some aspects, one or more medicaments in a liquid carrier solution are administered simultaneously with 2 to 50 (each integer included in the specified range) subdoses. In some aspects, one or more medicaments in a liquid carrier solution are administered simultaneously with 2 to 25 (each integer included in the specified range) subdoses. In some aspects, one or more medicaments in a liquid carrier solution are administered simultaneously with 2 to 15 (each integer included in the specified range) subdoses. In some aspects, one or more medicaments in a liquid carrier solution are administered simultaneously with 2 to 10 subdoses.In some aspects, one or more agents in a liquid carrier solution are administered simultaneously in subdoses of about 2 subdoses, about 5 subdoses, about 10 subdoses, about 15 subdoses, about 20 subdoses, about 25 subdoses, about 30 subdoses, about 35 subdoses, about 40 subdoses, about 45 subdoses, about 50 subdoses, about 75 subdoses, about 80 subdoses, about 85 subdoses, about 90 subdoses, about 95 subdoses, about 100 subdoses, about 150 subdoses, about 200 subdoses, about 250 subdoses, about 300 subdoses, about 350 subdoses, about 400 subdoses, about 450 subdoses, about 500 subdoses, about 00 subdoses, about 600 subdoses, about 700 subdoses, about 800 subdoses, about 900 subdoses, about 1,000 subdoses, about 2,000 subdoses, about 3,000 subdoses, about 4,000 subdoses, about 5,000 subdoses, about 6,000 subdoses, about 7,000 subdoses, about 8,000 subdoses, about 9,000 subdoses, about 10,000 subdoses, about 15,000 subdoses, about 20,000 subdoses, about 25,000 subdoses, about 30,000 subdoses, about 35,000 subdoses, about 40,000 subdoses, about 45,000 subdoses or about 50,000 subdoses. In some aspects, the above subdoses can be administered by a suitable delivery structure as further described herein.
[0119] In some embodiments described herein, for targeted delivery to one or more susceptible tumors, the flow rate of one or more agents administered to the skin according to a single delivery structure as described herein can be from about 0.01 μl / h to about 500 μl / h, including each integer in the specified range. In some aspects, the controlled flow rate of one or more agents administered according to a single delivery structure as described herein can be from about 0.01 μl / hour to about 250 μl / hour, including each integer in the specified range. In some aspects, the controlled flow rate of one or more administered agents according to a single delivery structure as described herein can be from about 0.01 μl / hour to about 150 μl / hour, including each integer in the specified range. In some aspects, the controlled flow rate of one or more agents administered according to a single delivery structure as described herein can be from about 0.01 μl / hour to about 100 μl / h, including each integer in the specified range. In some aspects, the controlled flow rate of one or more agents administered according to a single delivery structure as described herein can be from about 0.01 μl / h to about 50 μl / h, including each integer in the specified range. In some aspects, the controlled flow rate of one or more pharmaceutical agents administered according to a single delivery structure as described herein can be about 0.01 μl / h to about 25 μl / h, including each integer in the specified range. In some aspects, the controlled flow rate of one or more pharmaceutical agents administered according to a single delivery structure as described herein can be about 0.01 μl / h, about 0.5 μl / h, about 1 μl / h, about 1.5 μl / h, about 2 μl / h, about 2.5 μl / h, about 3 μl / h, about 3.5 μl / h, about 4 μl / h, about 4.5 μl / h, about 5 μl / h, about 10 μl / h, about 15 μl / h, about 20 μl / h, about 25 μl / h, about 30 μl / h, about 3 5μl / h, about 40μl / h, about 45μl / h, about 50μl / h, about 60μl / h, about 70μl / h, about 80μl / h, about 90μl / h, about 100μl / h, about 125μl / h, about 150μl / h, about 175μl / h, about 200μl / h, about 225μl / h, about 250μl / h, about 300μl / h, about 350μl / h, about 400μl / h, about 450μl / h, about 500μl / h.
[0120] In some embodiments described herein, the overall controlled flow rate of one or more agents administered to a subject as described herein can be from about 0.02 μl / h to about 50,000 μl / h, including each integer in the specified range, and the flow rate causes one or more agents to be taken up by one or more susceptible tumors. In some aspects, the overall controlled flow rate of one or more administered agents described herein can be from about 0.02 μl / h to about 25,000 μl / h, including each integer in the specified range. In some aspects, the overall controlled flow rate of one or more administered agents described herein can be from about 0.02 μl / h to about 15,000 μl / h, including each integer in the specified range. In some aspects, the overall controlled flow rate of one or more administered agents described herein can be from about 0.02 μl / h to about 10,000 μl / h, including each integer in the specified range. In some aspects, the overall controlled flow rate of one or more administered agents described herein can be from about 0.02 μl / h to about 5,000 μl / h, including each integer in the specified range. In some aspects, the overall controlled flow rate of one or more administered agents described herein can be from about 0.02 μl / h to about 2,500 μl / h, including each integer in the specified range. In some aspects, the overall controlled flow rate of one or more administered agents described herein can be from about 0.02 μl / h to about 1,250 μl / h, including each integer in the specified range. In some aspects, the overall controlled flow rate of one or more administered agents described herein can be from about 0.02 μl / h to about 500 μl / h, including each integer in the specified range. In some aspects, the overall controlled flow rate of one or more administered agents described herein can be from about 0.02 μl / h to about 250 μl / h, including each integer in the specified range. In some aspects, the overall controlled flow rate of one or more administered agents described herein can be from about 0.02 μl / h to about 125 μl / h, including each integer in the specified range. In some aspects, the overall controlled flow rate of one or more administered agents described herein can be from about 0.02 μl / h to about 50 μl / h, including each integer in the specified range. In some aspects, the overall controlled flow rate of one or more administered agents described herein can be from about 0.02 μl / h to about 25 μl / h, including each integer in the specified range. In some aspects, the overall controlled flow rate of one or more administered agents described herein can be from about 0.02 μl / h to about 10 μl / h, including each integer in the specified range.In some aspects, the overall controlled flow rate of one or more of the agents described herein can be about 0.02 μl / h, about 0.5 μl / h, about 1 μl / h, about 1.5 μl / h, about 2 μl / h, about 2.5 μl / h, about 3 μl / h, about 3.5 μl / h, about 4 μl / h, about 4.5 μl / h, about 5 μl / h, about 10 μl / h, about 15 μl / h, about 20 μl / h, about 25 μl / h, about 30 μl / h, about 35 μl / h, about 40 μl / h, about 45 μl / h, about 50 μl / h, about 6 0μl / h, about 70μl / h, about 80μl / h, about 90μl / h, about 100μl / h, about 125μl / h, about 150μl / h, about 175μl / h, about 200μl / h, about 225μl / h, about 250μl / h, about 300μl / h, about 350μl / h, about 400μl / h, about 450μl / h, about 500μl / h, about 550μl / h, about 600μl / h, about 650μl / h, about 700μl / h, about 750μl / h, about 800μl / h, about 850 μl / h, about 900 μl / h, about 950 μl / h, about 1,000 μl / h, about 1,250 μl / h, about 1,500 μl / h, about 1,750 μl / h, about 2,000 μl / h, about 2,250 μl / h, about 2,500 μl / h, about 2,750 μl / h, about 3,000 μl / h, about 3,250 μl / h, about 3,500 μl / h, about 3,750 μl / h, about 4,000 μl / h, about 4,250 μl / h, about 4,500 μl / h, About 4,750 μl / h, about 5,000 μl / h, about 5,500 μl / h, about 6,000 μl / h, about 6,500 μl / h, about 7,000 μl / h, about 7,500 μl / h, about 8,000 μl / h, about 8,500 μl / h, about 9,000 μl / h, about 9,500 μl / h, about 10,000 μl / h, about 10,000 μl / h, about 20,000 μl / h, about 30,000 μl / h, about 40,000 μl / h or about 50,000 μl / h.
[0121] In some embodiments described herein, the combined overall controlled flow rate of one or more pharmaceutical agents administered to the skin of a subject as described herein can range from about 0.02 μl / h / cm based on the total surface area of the delivery device as further described herein in contact with the skin of the subject. 2 to about 50,000 μl / h / cm 2, including each integer within the specified range. In the following aspects, the delivery rate based on the total surface area described herein results in one or more agents being taken up by one or more susceptible tumors. In one aspect, the total surface area of the delivery device refers to the two-dimensional surface area of the delivery device backing substrate in contact with the subject's skin. In another aspect, the total surface area of the delivery device refers to the combined total two-dimensional cross-sectional surface area of each of the independent delivery structures in contact with the subject's skin. In some aspects, the overall controlled flow rate range of one or more administered agents described herein can be about 0.02 μl / h / cm 2 to about 50,000 μl / h / cm 2 , including each integer within the specified range. In some aspects, the overall controlled flow rate range of one or more administered agents described herein can be about 0.02 μl / h / cm 2 to about 15,000 μl / h / cm 2 , including each integer within the specified range. In some aspects, the overall controlled flow rate range of one or more administered agents described herein can be about 0.02 μl / h / cm 2 to about 10,000 μl / h / cm 2 , including each integer within the specified range. In some aspects, the overall controlled flow rate range of one or more administered agents described herein can be about 0.02 μl / h / cm 2 to about 5,000 μl / h / cm 2 , including each integer within the specified range. In some aspects, the overall controlled flow rate range of one or more administered agents described herein can be about 0.02 μl / h / cm 2 to about 2,500 μl / h / cm 2 , including each integer within the specified range. In some aspects, the overall controlled flow rate range of one or more administered agents described herein can be about 0.02 μl / h / cm 2 to about 1,250 μl / h / cm 2 , including each integer within the specified range. In some aspects, the overall controlled flow rate range of one or more administered agents described herein can be about 0.02 μl / h / cm 2 to about 500 μl / h / cm 2 , including each integer within the specified range. In some aspects, the overall controlled flow rate range of one or more administered agents described herein can be about 0.02 μl / h / cm 2 to about 250 μl / h / cm 2 , including each integer within the specified range. In some aspects, the overall controlled flow rate range of one or more administered agents described herein can be about 0.02 μl / h / cm 2 to about 125 μl / h / cm2 , including each integer within the specified range. In some aspects, the overall controlled flow rate range of one or more administered agents described herein can be about 0.02 μl / h / cm 2 to about 50 μl / h / cm 2 , including each integer within the specified range. In some aspects, the overall controlled flow rate range of one or more administered agents described herein can be about 0.02 μl / h / cm 2 to about 25 μl / h / cm 2 , including each integer within the specified range. In some aspects, the overall controlled flow rate range of one or more administered agents described herein can be about 0.02 μl / h / cm 2 to about 10 μl / h / cm 2 , including each integer within the specified range. In some aspects, the overall controlled flow rate range of one or more administered agents described herein can be about 0.02 μl / h / cm 2 to about 5 μl / h / cm 2 , including every integer within the specified range. In some aspects, the overall controlled flow rate of one or more pharmaceutical agents described herein can be about 0.02 μl / h / cm 2 , about 0.5μl / h / cm 2 , about 1μl / h / cm 2 , about 1.5μl / h / cm 2 , about 2μl / h / cm 2 , about 2.5μl / h / cm 2 , about 3μl / h / cm 2 , about 3.5μl / h / cm 2 , about 4μl / h / cm 2 , about 4.5μl / h / cm 2 , about 5μl / h / cm 2 , about 10μl / h / cm 2 , about 15μl / h / cm 2 , about 20μl / h / cm 2 , about 25μl / h / cm 2 , about 30μl / h / cm 2 , about 35μl / h / cm 2 , about 40μl / h / cm 2 , about 45μl / h / cm 2 , about 50μl / h / cm 2 , about 60μl / h / cm 2 , about 70μl / h / cm 2 , about 80μl / h / cm 2 , about 90μl / h / cm2 , about 100μl / h / cm 2 , about 125μl / h / cm 2 , about 150μl / h / cm 2 , about 175μl / h / cm 2 , about 200μl / h / cm 2 , about 225μl / h / cm 2 , about 250μl / h / cm 2 , about 300μl / h / cm 2 , about 350μl / h / cm 2 , about 400μl / h / cm 2 , about 450μl / h / cm 2 , about 500μl / h / cm 2 , about 550μl / h / cm 2 , about 600μl / h / cm 2 , about 650μl / h / cm 2 , about 700μl / h / cm 2 , about 750μl / h / cm 2 , about 800μl / h / cm 2 , about 850μl / h / cm 2 , about 900μl / h / cm 2 , about 950μl / h / cm 2 , about 1,000μl / h / cm 2 , about 1,250μl / h / cm 2 , about 1,500μl / h / cm 2 , about 1,750μl / h / cm 2 , about 2,000μl / h / cm 2 , about 2,250μl / h / cm 2 , about 2,500μl / h / cm 2 , about 2,750μl / h / cm 2 , about 3,000μl / h / cm 2 , about 3,250μl / h / cm 2 , about 3,500μl / h / cm 2 , about 3,750μl / h / cm 2 , about 4,000μl / h / cm 2 , about 4,250μl / h / cm 2 , about 4,500μl / h / cm 2 , about 4,750μl / h / cm 2 , about 5,000μl / h / cm 2, about 5,500μl / h / cm 2 , about 6,000μl / h / cm 2 、About 6,500μl / h / cm 2 , about 7,000μl / h / cm 2 , about 7,500μl / h / cm 2 , about 8,000μl / h / cm 2 , about 8,500μl / h / cm 2 , about 9,000μl / h / cm 2 , about 9,500μl / h / cm 2 , about 10,000μl / h / cm 2 , about 20,000μl / h / cm 2 , about 30,000μl / h / cm 2 , about 40,000μl / h / cm 2 or about 50,000 μl / h / cm 2 .
[0122] In some embodiments described herein, for targeted delivery to one or more susceptible tumors, the flow rate of one or more agents administered to the skin according to a single delivery structure as described herein can be from about 0.01 μl / h to about 500 μl / h.
[0123] In some embodiments described herein, one or more agents administered to a subject as described herein may have a flow rate of about 0.2 μl / h to about 50,000 μl / h that results in uptake of the one or more agents by one or more susceptible tumors.
[0124] In the embodiments described herein, the combined overall controlled flow rate of one or more pharmaceutical agents administered to the skin of a subject as described herein can range from about 0.02 μl / h / cm based on the total surface area of the delivery device as further described herein in contact with the skin of the subject. 2 to about 50,000 μl / h / cm 2 In one aspect, the total surface area of a delivery device refers to the two-dimensional surface area of the delivery device backing substrate in contact with the subject's skin. In another aspect, the total surface area of a delivery device refers to the combined total two-dimensional cross-sectional surface area of each of the individual delivery structures in contact with the subject's skin.
[0125] In some embodiments, the methods described herein provide for the increased delivery of one or more agents to one or more lymphatic tissues for targeted delivery to one or more susceptible tumors. In some aspects, one or more agents travel to one or more lymph nodes or one or more tumor sites through the lymphatic system. Without being bound by any theory, it is believed that one or more agents are taken up by the lymphatic system to achieve the delivery of one or more agents to the position around the susceptible tumor. In addition, the tumor triggers a lymphangiogenic response, which can further increase the local lymphatic system around the susceptible tumor, thereby achieving drug delivery. In addition, without being limited to theory, it is also believed that increasing the delivery of one or more bioactive agents (e.g., anticancer agents) through the lymphatic system can limit the metastatic spread of tumors through peripheral lymphatic vessels by producing local cytotoxicity or therapeutic effects against potential metastatic cancer cells.
[0126] As further described herein, the physiology and hydrostatics of the lymphatic system play an important role in mammalian physiology and an untapped resource for delivering drugs to tumors. The lymphatic system includes all lymphatic endothelial cells that make up the capillaries, larger lymphatic vessels, and collecting ducts. The fluid within the lymphatic system and all biological substances in the fluid are ultimately drained into one or more lymph nodes and ultimately into the bloodstream to enter the systemic circulation. For a complete review of lymphatic physiology, see William N. Charman and Valentino J. Stella, Lymphatic Transport of Drugs (1992), which is incorporated herein by reference in its entirety.
[0127] The lymphatic system is part of the immune system and protects the body from infection and invasion by foreign organisms. Lymphocytes and macrophages patrol most body tissues for invading viruses, bacteria, tumor cells, foreign proteins, toxins, damaged and dead cells, and foreign cells including foreign tissue grafts. Lymphatic vessels connect to most tissues and transport lymph fluid carrying immune cells to lymph nodes and lymphatic organs such as the spleen and thymus. Lymphatic vessels, also called lymphatics or the lymphatic vasculature, are a network of thin, opaque, tubular structures that branch like blood vessels into tissues throughout the body. In mammals, including humans, most tissues and organs are drained by the lymphatic system.
[0128] Unlike the circulatory system, the lymphatic system is open and has no central pump. The lymphatic system forms a one-way flow system toward the heart. A complex network of capillary lymphatic vessels draws interstitial fluid from the tissues, which is then called lymph. Lymphatic vessels enter all tissues except epithelial cells, brain, spinal cord, and bone marrow. Some connective tissues (such as cartilage and cornea) have no blood vessels and no lymphatic vessels. Lymph moves slowly under the low pressure created by peristaltic contractions.
[0129] The diameter of these lymphatic capillaries is ten to fifty microns. They start with a blind end, or anastomosis. The endothelium is a single layer with an incomplete basement membrane. They have gap junctions that are highly permeable to plasma proteins and large particles (including, for example, carbon particles), pathogens (such as viruses, bacterial cells and parasites), cells (including, for example, immune cells and tumor cells) and cell fragments. Lymphatic capillaries have a one-way valve that ensures that flow is only in one direction. When the interstitial fluid pressure outside the lymphatic capillaries is greater than the pressure inside the capillaries, the flap opens to allow liquid to enter. On the contrary, when the pressure inside the capillaries is larger, the flap is forced to close, excluding any lymph fluid leaking from the blood vessels. During inflammation, capillary formation allows the ingestion of even larger molecules and cell fragments.
[0130] Lymph flows from the capillaries into collecting lymphatic vessels, where it encounters the first of many lymph nodes. These "afferent" lymphatic vessels carry lymph to the lymph nodes, and the "efferent" lymphatic vessels carry lymph away from the lymph nodes. Lymph is a colorless, aqueous fluid derived from interstitial fluid. Lymph originates from plasma lost from the capillary beds of the circulatory system, which leaks into the surrounding tissues. Although the capillaries of the circulatory system cause only about 1% of the volume of fluid that passes through them to reach the interstitial tissue, however, so much blood circulates that the average human cumulative fluid loss is about three liters / day. The lymphatic system recaptures this fluid by diffusing into the lymphatic capillaries, and filters it through various lymph nodes and returns it to the circulatory system through the thoracic duct. Once in the lymphatic system, the fluid is called lymph and has a composition that is almost the same as the original interstitial fluid.
[0131] Lymphatic capillaries are ubiquitous throughout the body. Non-limiting examples of such locations include viable skin (dermis), tendons, striated muscle, muscle sheaths, periosteum, joint capsules, submesothelial lining of the pleura, peritoneum, and pericardial cavities, digestive tract, salivary glands, liver, spleen, nasal cavity, trachea, bronchi, thyroid gland, thymus gland, adrenal gland, kidney, bladder, urethra, prostate gland, testicles, uterus, ovaries, and heart.
[0132] Lymph nodes filter lymph, where the inner honeycomb structure of connective tissue is filled with lymphocytes that collect and destroy bacteria and viruses. Lymph nodes also produce lymphocytes and antibodies. When the body fights infection, these lymphocytes multiply rapidly and produce the characteristic swelling of the lymph nodes. Lymph is transported to progressively larger lymphatic vessels, terminating in the right lymphatic duct (for lymph from the right upper body) and the thoracic duct (for the rest of the body). These ducts drain into the circulatory system at the right and left subclavian veins near the shoulders. Along the network of lymphatic vessels is a series of various lymphatic tissues and organs, including lymph follicles, Peyer's patches, tonsils, lymph nodes, thymus, and spleen.
[0133] Lymph follicles are temporary lymphocyte clusters that form at the site of infection and then disappear. The mantle (capsule) or external covering does not separate the nodule from the surrounding cells and fluid, but directly penetrates into the nodule. Lymph nodes wrap many lymph follicles in the tough mantle and provide blood vessels and lymphatic vessels. Lymph nodes filter lymph delivered to them by lymphatic vessels. Therefore, lymph nodes filter lymph drawn from the capillary lymphatic beds where lymph nodes are located. Peyer's patches are larger nodular clusters of lymphocytes located in the intestinal wall, and tonsils are capsules of nodular tissue wrapped in the pharyngeal mucosa. Peyer's patches and tonsils are positioned to intercept antigens from the digestive tract and respiratory tract, respectively.
[0134] The spleen, lymph nodes, and accessory lymphoid tissues (including tonsils and appendix) are secondary lymphoid organs. These organs consist of a connective tissue scaffold that supports circulating B- and T-lymphocytes and other immune cells (including, for example, macrophages, dendritic cells, and eosinophils). When microorganisms invade the body or the body encounters other antigens, the antigens are usually transported from the tissues to the lymph. The lymph is carried to the regional lymph nodes in the lymphatic vessels.
[0135] In the lymph nodes, macrophages and dendritic cells engulf the antigen, process it, and present it to lymphocytes, which can then begin to produce antibodies or act as memory cells to recognize the antigen again in the future. Lymph fluid and lymphatic tissue therefore contain antibodies and immune cells.
[0136] Fluid from the interstitial tissue has a wide range of lymphatic absorption rates. For example, it has been estimated that the percentage of water drained from the intestinal site via the lymphatic vessels ranges from anywhere between 1% to nearly 85%, with other estimates suggesting that the lymphatic system is responsible for absorbing between 15% and 20% of the interstitial fluid. This discrepancy may be due to the immediate physiological state of the lymphatic tissue being measured.
[0137] Lymphatic capillaries are widely distributed throughout the skin of mammals. Specifically, it has been found that certain areas such as fingers and palms, the soles of the feet and toes, and the scrotum have the highest lymphatic distribution. The skin lymphatic vessels are mainly composed of superficial lymphatic plexuses in the dermis, which extend upward to the outer two-thirds of the dermal structure into the papillary dermis. The deeper plexuses are located near the subcutaneous tissue boundary in the reticular dermis area within the dermis. Generally speaking, very little or no lymphatic tissue is found in the epidermis or subcutaneous tissue layer. In the area of skin with a thicker dermis (for example, the palm surface of the hand and the sole of the foot), the lymphatic vessels are usually more uniform. Similar to intestinal tissue, the absorption of interstitial fluid and protein in the skin is highly variable, for example, in animal models, the lymphatic flow in the skin area is about 1 ml / h / 100g tissue, which can increase more than 10 times, depending on the local physiology around the lymphatic system. Various factors have been found to influence lymphatic absorption, including venous pressure, contraction of surrounding tissues and blood vessels, and respiratory rate. For example, the Starling equation describes the production of interstitial fluid by the competition of hydrostatic and oncotic forces on the semipermeable capillary walls. Thus, increasing intravascular hydrostatic pressure or decreasing intravascular osmotic pressure or increasing capillary permeability tends to increase interstitial fluid volume and promote subsequent fluid absorption by lymphatic capillaries or lead to edema.
[0138] Absorption of proteins and lipids is also highly variable and depends largely on fluid absorption rate, location within the skin, and size of the molecule. In general, the size and lipophilicity or hydrophilicity of the molecule play a large role in its relative absorption. For example, and without being limited by any theory, it is believed that molecules less than 10 kDa are absorbed by capillaries and lymphatic capillaries at approximately the same rate, while molecules greater than 20 kDa are more likely to enter the lymphatic vessels, depending on the physiological state of the given local lymphatic capillaries as described above.
[0139] Therefore, it is widely understood that delivery to the lymphatic system would be highly desirable due to the ubiquitous nature of lymphatic capillaries and the ability to absorb a large number of agents of varying sizes. The involvement of the lymphatic system in the development and spread of inflammation and various cancers described above provides an important alternative approach for local and systemic treatment of cancer and cancer tumors.
[0140] In some embodiments described herein, one or more medicaments are directly delivered to a certain position in the epidermis. In some aspects, one or more medicaments diffuse, move, flow or migrate to a position close to the lymphatic system. As described herein, this arrangement in the epidermis after the method described herein causes the medicament to diffuse or move through the epidermis and the viable epidermis and enter the top layer of the dermis. This type of movement provided by the delivery method described herein allows the direct contact of the medicament with the capillary lymphatic bed (or referred to as the lymphatic drainage bed or the capillary lymphatic plexus) present in the shallowest layer, and the capillary lymphatic bed is physiologically used as the interstitial fluid of a given position is drained to the remainder of the lymphatic system. Local delivery of one or more medicaments to the capillary lymphatic bed can result in the medicament being delivered to the first lymph node (also referred to as "primary" lymph node) of the drainage capillary lymphatic bed. In some aspects, the local delivery of one or more medicaments can also result in the medicament being delivered to the other lymph nodes (also referred to as "secondary" lymph nodes) downstream of the primary lymph node. In some aspects, the medicament may eventually enter the bloodstream and be systemically delivered to one or more tumors. In some aspects, the agent can be delivered via the lymphatic vasculature within or in close proximity to a solid tumor or to a tumor residing in one or more lymph nodes.
[0141] Thus, some embodiments described herein include methods for local delivery of one or more agents to lymphatic tissues including one or more lymphatic capillaries, lymph follicles, lymph nodes, Peyer's patches and / or tonsils. In some aspects, the methods described herein are suitable for delivery to one or more lymph nodes in any tissue or region of the body. Suitable non-limiting examples include lymph nodes present in the hands, feet, thighs (femoral lymph nodes), arms, legs, armpits (axillary lymph nodes), groin (inguinal lymph nodes), neck (cervical lymph nodes), chest (thoracic lymph nodes), abdomen (iliac lymph nodes), popliteal lymph nodes, parasternal lymph nodes, lateral aortic lymph nodes, para-aortic lymph nodes, submental lymph nodes, parotid lymph nodes, submandibular lymph nodes, supraclavicular lymph nodes, intercostal lymph nodes, diaphragmatic lymph nodes, pancreatic lymph nodes, cisterna chyli, lumbar lymph nodes, sacral lymph nodes, obturator lymph nodes, mesenteric lymph nodes, mesocolon lymph nodes, mediastinal lymph nodes, gastric lymph nodes, hepatic lymph nodes, and splenic lymph nodes.
[0142] In some embodiments described herein, it is a method for delivering one or more agents to a susceptible capillary lymphatic plexus of a mammal to target one or more agents to one or more susceptible tumors. In some aspects, one or more agents are delivered to a tissue area with a susceptible capillary lymphatic plexus. In some aspects, one or more agents are delivered to a viable area of the skin with a susceptible capillary lymphatic plexus. In some aspects, the susceptible capillary lymphatic plexus is located in the region of the viable dermis as described herein. In some aspects, the susceptible capillary lymphatic plexus is easy to absorb one or more agents from the local surrounding interstitial tissue. In some aspects, due to the local physiological environment, the susceptible capillary lymphatic plexus is easy to absorb one or more agents from the local surrounding interstitial tissue. In some aspects, the local physiological environment is easy to absorb one or more agents due to the presence of the following items: inflammation, interstitial fluid pressure higher than the pressure in the lymphatic vessels, higher capillary fluid exchange rate, tissue contraction, respiration or its combination factors. In one aspect, the susceptible lymphatic capillary plexus has a lower pressure inside the lymphatic capillaries than the surrounding interstitial fluid in which the one or more agents are located, thereby increasing the local absorption rate of the one or more agents by the lymphatic capillary plexus. In another aspect, the susceptible lymphatic capillary plexus and the one or more agents are located in an inflammatory area (e.g., from cancer), wherein the local inflammation promotes the porosity of the lymphatic capillary plexus, thereby increasing the local absorption rate of the one or more agents delivered thereto.
[0143] In some embodiments described herein, one or more medicaments are delivered to a region in the viable skin (e.g., viable dermis) having one or more susceptible capillary lymphatic plexuses. In some aspects, the delivery method includes applying one or more medicaments in a suitable vehicle to the skin at a controlled rate, wherein the one or more medicaments surround the one or more susceptible capillary lymphatic plexuses. In some aspects, the one or more medicaments are delivered as a suspension or solution in a liquid carrier. Without being bound by any theory, it is believed that one or more medicaments applied at a controlled rate in a liquid carrier solution, wherein the one or more capillary lymphatic plexuses are surrounded by a solution containing the one or more medicaments, can enhance the absorption of the capillary lymphatic plexus to it. Similarly, without being bound by any theory, it is believed that the absorption of the solution containing the one or more medicaments can be attributed to the increase in the local dermal interstitial fluid pressure around the capillary lymphatic plexus.
[0144] In some embodiments described herein, it is a method for matching the physiological absorption rate of one or more susceptible capillary lymphatic plexuses with a liquid carrier solution having one or more medicaments. In some aspects described herein, the method for matching the tissue absorption rate of susceptible capillary lymphatic plexuses includes increasing the local tissue fluid pressure or tissue hydrostatic pressure around one or more capillary lymphatic plexuses. The absorption rate of the capillary lymphatic plexuses will depend on many factors (such as capillary flow rate and filtration rate, tissue osmotic pressure and hydrostatic pressure and tissue compliance, etc.) as further described herein. Without being bound by any theory, the relatively small increase of local interstitial tissue hydrostatic pressure usually increases the rate of lymphatic absorption. Under the lower tissue interstitial tissue absorption rate, lymphatic vessels are the main way of fluid removal. When interstitial fluid is drained from interstitial tissue fluid to capillary lymphatic vessels, interstitial fluid carries various proteins and other biological particles. In the case of not significantly reducing tissue osmotic pressure, the increase of tissue hydrostatic pressure caused preferentially forces fluid to enter the lymphatic vessels rather than the capillaries, due to the overall increase of the fluid pressure conductivity of the lymphatic vessels. On the contrary, under relatively high interstitial tissue absorption rate, capillaries are usually the main way of fluid removal. This is usually because as the increased fluid is pushed into the interstitial tissue, the tissue osmotic pressure is reduced, thereby forcing the fluid to enter the capillaries due to the relatively high capillary osmotic pressure. In addition, the presence of medium to high levels of interstitial tissue fluid increases the pressure on the extracellular matrix, thereby increasing tissue compliance (e.g., tissue expansion) and the overall reduction of hydrostatic pressure. This causes lymphatic drainage to decrease. Therefore, interstitial hydrostatic pressure and osmotic pressure exert forces on the capillary wall, and only tissue pressure has an impact on lymphatic drainage.
[0145] In some embodiments described herein, the fluid containing one or more medicaments in the liquid carrier solution is applied to achieve an increase in local dermal interstitial fluid pressure to promote lymphatic uptake of one or more medicaments. Not limited by any theory, it is believed that interstitial fluid pressure is greater than about 1mmHg to about 3mmHg, resulting in interstitial fluid (e.g., dermal interstitial fluid) lymphatic drainage. The pressure of this amount causes the opening of the pressure-responsive lymph valve as described herein, thereby allowing interstitial fluid to be drained into the capillary lymphatic vessels. In some aspects, the dermis area where the dermal interstitial fluid pressure is increased due to the application of one or more medicaments described herein is below the application site in the epidermis. In some aspects, a specific interstitial tissue pressure value can be about 1mmHg to about 15mmHg. In some aspects, the interstitial tissue pressure value can be increased to about 1mmHg to about 10mmHg by the method described herein. In some aspects, a specific interstitial tissue pressure value can be increased to about 1mmHg to about 5mmHg by the method described herein. In some aspects, a particular interstitial tissue pressure value can be increased by the methods described herein to greater than about 1 mmHg, greater than about 2 mmHg, greater than about 3 mmHg, greater than about 4 mmHg, greater than about 5 mmHg, greater than about 6 mmHg, greater than about 7 mmHg, greater than about 8 mmHg, greater than about 9 mmHg, greater than about 10 mmHg, greater than about 11 mmHg, greater than about 12 mmHg, greater than about 13 mmHg, greater than about 14 mmHg, greater than about 15 mmHg, greater than about 16 mmHg, greater than about 17 mmHg, greater than about 18 mmHg, greater than about 19 mmHg, or greater than about 20 mm Hg.
[0146] Any method known in the art for assessing interstitial fluid pressure can be used. For example, micropipettes, wick-in-needle or wicking catheter techniques show a high level of intra-assay accuracy and can be used to assess the hydrostatic pressure around a probe segment inserted into a subject's interstitial space (e.g., dermal interstitial space) while administering a medicament using the methods described herein or after administering a medicament. See, e.g., Wiig and Swartz., Phsiol. Rev., 1005-1060, (2012), which is incorporated herein by reference for teachings herein.
[0147] In some embodiments described herein, the methods for controlled delivery described herein result in one or more active drug substances being deposited in one or more lymph nodes or lymphatic tissues. In some aspects, the concentration of one or more active drug substances is about 0.5% to about 75% of the initial dosage per gram of lymph node tissue, including each integer within the specified range. In some aspects, the concentration of one or more active drug substances is about 0.5% to about 50% of the initial dosage per gram of lymph node tissue, including each integer within the specified range. In some aspects, the concentration of one or more active drug substances is about 0.5% to about 25% of the initial dosage per gram of lymph node tissue, including each integer within the specified range. In some aspects, the concentration of one or more active drug substances is about 0.5% to about 15% of the initial dosage per gram of lymph node tissue, including each integer within the specified range. In some aspects, the concentration of one or more active drug substances is about 0.5% to about 10% of the initial dosage per gram of lymph node tissue, including each integer within the specified range. In some aspects, the concentration of one or more active drug substances is about 0.5% to about 5% of the initial dosage per gram of lymph node tissue, including each integer within the specified range. In some aspects, the concentration of one or more active drug substances is about 10% to about 60% of the initial dosage of each gram of lymph node tissue, including each integer in the specified range. In some aspects, the concentration of one or more active drug substances is about 30% to about 55% of the initial dosage of each gram of lymph node tissue, including each integer in the specified range. In some aspects, the concentration of one or more active drug substances is about 40% to about 50% of the initial dosage of each gram of lymph node tissue, including each integer in the specified range. In some aspects, the concentration of one or more active drug substances is about 0.5%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70% or about 75% of the initial dosage of each gram of lymph node tissue.
[0148] In some embodiments described herein, the methods for controlled delivery described herein result in deposition of one or more active drug substances in one or more lymph nodes, wherein after about 36 hours, the ratio of the initial dose of one or more agents concentrated per gram of lymph node tissue to the concentration per gram of whole blood tissue is about 2: 1 to about 50: 1, including all ratios within the specified range. In some aspects, after about 36 hours, the ratio of the initial dose of one or more agents concentrated per gram of lymph node tissue to the concentration per gram of whole blood tissue is about 2: 1 to about 25: 1, including all ratios within the specified range. In some aspects, after about 36 hours, the ratio of the initial dose of one or more agents concentrated per gram of lymph node tissue to the concentration per gram of whole blood tissue is about 2: 1 to about 15: 1, including all ratios within the specified range. In some aspects, after about 36 hours, the ratio of the initial dose of one or more agents concentrated per gram of lymph node tissue to the concentration per gram of whole blood tissue is about 2: 1 to about 10: 1, including all ratios within the specified range. In some aspects, after about 36 hours, the ratio of the initial dose of one or more agents per gram of lymph node tissue concentrate to the ratio of the initial dose of one or more agents per gram of whole blood tissue concentrate is about 2: 1 to about 5: 1, including all ratios within the specified range. In some aspects, the ratio of the initial dose of one or more agents per gram of lymph node tissue concentrate to the ratio of the initial dose of one or more agents per gram of whole blood tissue concentrate is about 2: 1, about 3: 1, about 4: 1, about 5: 1, about 6: 1, about 7: 1, about 8: 1, about 9: 1, about 10: 1, about 12: 1, about 14: 1, about 16: 1, about 18: 1, about 20: 1, about 25: 1, about 30: 1, about 35: 1, about 40: 1, about 45: 1, or about 50: 1.
[0149] In some embodiments described herein, the methods for controlled delivery described herein result in deposition of one or more active drug substances in one or more lymph nodes, wherein after about 36 hours, the ratio of the initial dose of one or more agents concentrated per gram of lymph node tissue to that concentrated per gram of skin is from about 0.1:1 to about 3:1, including all ratios within the specified range. In some aspects, after about 36 hours, the ratio of the initial dose of one or more agents concentrated per gram of lymph node tissue to that concentrated per gram of skin is from about 0.25:1 to about 3:1, including all ratios within the specified range. In some aspects, after about 36 hours, the ratio of the initial dose of one or more agents concentrated per gram of lymph node tissue to that concentrated per gram of skin is from about 0.5:1 to about 3:1, including all ratios within the specified range. In some aspects, after about 36 hours, the ratio of the initial dose of one or more agents concentrated per gram of lymph node tissue to that concentrated per gram of skin is from about 1:1 to about 3:1, including all ratios within the specified range. In some aspects, the ratio of the initial dose of one or more agents per gram of lymph node tissue focus to per gram of skin focus is about 0.1:1, about 0.2:1, about 0.4:1, about 0.6:1, about 0.8:1, or about 1:1, about 2:1, or about 3:1.
[0150] Non-invasive quantitative methods for drug biodistribution and absorption pharmacokinetics of tissues are well known and are used to assess the percentage of drug absorption per initial dose per gram of tissue. The initial dosage percentage of one or more agents delivered per gram of lymph node tissue as described herein can be quantified by directly labeling one or more agents with a detectable radioactive marker and then administering the agent using the methods described herein. Imaging and quantification of radiolabeled agents can be assessed using standard positron emission tomography (PET) or single photon emission computed tomography (SPECT) or a combination of these techniques with X-ray computed tomography (CT) or magnetic resonance imaging (MRI), see, e.g., Ding and Wu., Theranostics, 2 (11), 1040-1053 (2012), which is incorporated herein by reference for teachings herein. Available radiolabels can include short-lived or long-lived isotopes, such as 11 C. 15 O. 18 F. 68 Ga, 64 Cu, 76 Br, 89 Zr, 124I. The radiolabel selected will depend on the agent being tested and the specific labeling schemes well known in the art. The initial dose absorption percentage per gram of lymph node tissue measured initially using PET or SPECT imaging can be calculated using standard radiopharmaceutical dosimetry and tissue density tables, see, Bolch et al., J. Nucl. Med., 50(3), 477 (2009), which is incorporated herein by reference for teachings herein.
[0151] Other comparative methods can be used to assess the amount of drug per gram of tissue delivered to lymphatic tissue. Suitable comparative methods include using any of the above-mentioned short-lived or long-lived isotopes to radiolabel one or more medicaments, and using the method described herein, the one or more medicaments labeled are administered to a suitable comparative test subject. Subjects can include experimental animals, such as rats, guinea pigs, mice or monkeys. In order to determine the biodistribution and percentage of the initial dosage delivered by per gram of lymphatic tissue, lymphatic tissue (such as one or more lymph nodes) in other related organs can be harvested from the test animal, and the well-known technical measurement of standard and the specific radioactivity count in the quantitative tissue can be used, and it is compared with the radioactivity measurement of the initial dosage.
[0152] In some embodiments described herein, the method for controlled delivery described herein results in more amounts being absorbed by one or more susceptible capillary lymphatic plexuses in the initial dosage of one or more medicaments compared to other traditional delivery routes, such as intravenous (iv), subcutaneous (sc), intramuscular (im) or intradermal (id) injection routes or traditional transdermal patches. In some respects, compared to iv, sc, im or id parenteral delivery routes, the controlled delivery method described herein results in an increase in lymphatic delivery of one or more medicaments by about 1.25 times to about 50 times, including each integer within a specified range. In some respects, compared to iv, sc, im or id parenteral delivery routes, the controlled delivery method described herein results in an increase in lymphatic delivery of one or more medicaments by about 1.25 times to about 20 times, including each integer within a specified range. In some respects, compared to iv, sc, im or id parenteral delivery routes, the controlled delivery method described herein results in an increase in lymphatic delivery of one or more medicaments by about 1.25 times to about 10 times, including each integer within a specified range. In some aspects, the controlled delivery methods described herein result in an increase in lymphatic delivery of one or more agents by about 1.25-fold to about 5-fold, including every integer in the specified range, compared to iv, sc, im or id parenteral delivery routes.
[0153] The evaluation and comparison of the absorption of one or more lymphatic capillaries by the agents delivered using the methods described herein can be determined by using one or more imaging agents connected to the agents or bioactive agents delivered using the methods described herein. These imaging agents can be used to image lymphatic capillaries and tissues, such as one or more lymphatic capillaries or lymph node tissue. Suitable imaging agents can be any agent that is biocompatible and has no biological activity or adverse effects. Exemplary and non-limiting imaging agents can be one or more agents for direct or indirect X-ray lymphangiography, one or more contrast agents for magnetic resonance imaging (MRI), one or more fluorescent imaging agents for fluorescent microlymphangiography (FML), or one or more fluorescent imaging agents for CG lymphatic system angiography that can be excited by near infrared light (NIR) that penetrates tissue. Techniques and agents for lymphatic imaging are known in the art, see, for example, Sevick-Muraca et al., J. Clin Invest., 124 (3), 905-914 (2014), which is incorporated herein by reference for teachings herein. Standard image analysis algorithms and software can be used to calculate the fluorophore intensity of delivered agents labeled or traced with imaging agents as described above and compared to traditional iv, sc, im or id parenteral delivery routes.
[0154] In some embodiments, the methods for controlled delivery described herein result in serum absorption rates equivalent to those of iv, sc, im or id parenteral delivery routes, while maintaining relatively high lymphatic delivery rates as described herein. Without being bound by any theory, the delivery rate may be attributed to the lymphatic circulation of one or more agents through the thoracic duct and into the blood circulation. Standard highly accurate and precise methods for measuring serum concentrations and therapeutic monitoring at desired time points, such as but not limited to radioimmunoassay, high performance liquid chromatography (HPLC), fluorescence polarization immunoassay (FPIA), enzyme immunoassay (EMIT) or enzyme-linked immunosorbent assay (ELISA) well known in the art can be used. In order to calculate the absorption rate using the above method, the drug concentration at several time points should be measured immediately after administration and then incrementally measured until C can be established. max values and calculate the associated absorption rate.
[0155] In some embodiments described herein are methods for controlled delivery of one or more agents in a liquid carrier solution as described herein to the skin to target the delivery of one or more agents to one or more susceptible tumors. In some aspects, the method comprises penetrating at least the shallowest layer of the epidermis with a delivery structure as described herein; contacting the epidermis with one or more penetration enhancers; and applying one or more agents in a liquid carrier solution at about 2 to 50,000 subdoses, wherein the subdoses are applied to the skin (e.g., non-viable epidermis and / or viable epidermis and / or viable dermis) at a depth of about 10 μm to about 4,500 μm or about 1 μm to about 4,000 μm beyond the shallowest layer of the epidermis, but still within the viable skin above the subcutaneous tissue; and wherein the administration comprises one or more of the following: (a) an administration flow rate that matches the lymphatic drainage rate of the tissue; (b) about 0.02 μl / h / cm based on the surface area of the delivery device or delivery structure. 2 to about 50,000 μl / h / cm 2 (c) an interstitial fluid pressure of greater than about 2 mmHg in the local vicinity of one or more susceptible lymphatic capillaries; and (d) delivering one or more agents to the skin in a liquid carrier, wherein the delivered fluid is approximately 0.7 mmHg. 3 To about 2,500mm 3 The three-dimensional tissue volume contacts or is contained by the three-dimensional tissue volume.
[0156] In some embodiments described herein is a method for controlled delivery of one or more active drug substances to the skin. In some aspects, the overall dose of one or more active drug substances in a liquid carrier is delivered to one or more susceptible tumors. In some aspects, the overall dose of one or more active drug substances in a liquid carrier is first delivered to one or more susceptible lymphatic capillaries, and then targeted delivery to one or more susceptible tumors. As described herein, the overall dose may include 2 to 50,000 subdoses. In some aspects, the overall dose of one or more active drug substances may include about 0.0001 mg / kg body weight to about 100 mg / kg body weight, including each integer within the specified range. In some aspects, the overall dose of one or more active drug substances may include about 0.001 mg / kg body weight to about 100 mg / kg body weight, including each integer within the specified range. In some aspects, the overall dose of one or more active drug substances may include about 0.01 mg / kg body weight to about 100 mg / kg body weight, including each integer within the specified range. In some aspects, the overall dose of one or more active drug substances may include about 0.1 mg / kg body weight to about 100 mg / kg body weight, including each integer within the specified range. In some aspects, the overall dose of one or more active drug substances may include about 0.1 mg / kg body weight to about 50 mg / kg body weight, including each integer within the specified range. In some aspects, the overall dose of one or more active drug substances may include about 0.1 mg / kg body weight to about 25 mg / kg body weight, including each integer within the specified range. In some aspects, the overall dose of one or more active drug substances may include about 0.1 mg / kg body weight to about 10 mg / kg body weight, including each integer within the specified range. In some aspects, the overall dose of one or more active drug substances may include about 0.1 mg / kg body weight to about 5 mg / kg body weight, including each integer within the specified range. In some aspects, the total dose of one or more active drug substances can include about 0.0001 mg / kg, about 0.001 mg / kg, about 0.01 mg / kg, about 0.1 mg / kg, about 0.5 mg / kg, about 1 mg / kg, about 2 mg / kg, about 3 mg / kg, about 4 mg / kg, about 5 mg / kg, about 6 mg / kg, about 7 mg / kg, about 8 mg / kg, about 9 mg / kg, about 10 mg / kg, about 20 mg / kg, about 30 mg / kg, about 40 mg / kg, about 50 mg / kg, about 60 mg / kg, about 70 mg / kg, about 80 mg / kg, about 90 mg / kg, or about 100 mg / kg.
[0157] In some embodiments described herein are methods for controlled delivery of one or more active drug substances to the skin. In some aspects, the overall dose of one or more active drug substances in a liquid carrier is delivered to one or more susceptible tumors. In some embodiments, the methods for controlled delivery described herein result in a serum absorption rate equivalent to that of iv, sc, im or id parenteral delivery routes while maintaining a relatively high lymphatic delivery rate as described herein. Without being bound by any theory, the delivery rate may be attributed to the lymphatic circulation of one or more medicaments through the thoracic duct and into the blood circulation.
[0158] In some embodiments, the method for controlled delivery described herein causes the physiological extension level of bioactive agent (e.g., active drug substance) to be higher than known effective treatment threshold. In some respects, the controlled delivery method described herein reduces or prevents the single rapid administration of one or more active drug substances described herein. In some respects, this can increase the safety of one or more bioactive agents by limiting the potential dangerous peak value of one or more bioactive agents in systemic plasma circulation. In addition, the controlled delivery method described herein can further increase the therapeutic ratio of one or more active drug substances administered by reducing the dosage required for treatment or beneficial effect.
[0159] In some embodiments, the controlled delivery methods described herein cause one or more agents to remain at the disease site (e.g., within one or more lymph nodes) and not spread throughout the body, thereby resulting in a reduction in the occurrence of known side effects of active drug substances. For example, in the case where the disease involves inflammation (e.g., cancer, infection, arthritis), one or more agents may be absorbed by susceptible capillary lymphatic plexus and distributed to the site of inflammation without further distribution to the systemic circulation. One or more agents can be distributed throughout the body by entering the systemic blood circulation through the thoracic duct through the lymphatic vascular system and lymphatic tissue circulation. Alternatively, one or more agents can be distributed throughout the body by being directly absorbed by one or more susceptible capillary plexus. In some aspects, one or more agents can then be absorbed by one or more susceptible tumors in the subject by extravasation from the tumor vascular system and entering the tumor stroma.
[0160] In some embodiments, the methods described herein for controlled delivery result in achieving maximum therapeutic efficacy or T max The relatively short period of time while maintaining a physiologically prolonged level of one or more active drug substances above an effective therapeutic threshold. max Can be independent of the C of the active drug substance max or total serum concentration and can be assessed by the perception of improvement in a disease or condition.
[0161] In some embodiments described herein, one or more bioactive agents delivered to the skin and subsequently delivered to one or more susceptible tumors by the methods described herein may include an active drug substance. For example, an active drug substance may be a compound (e.g., a small molecule) that can act on a cell receptor or surface protein and act as an agonist, antagonist, inverse agonist, etc., which results in a modification of the disease path and generally produces effective and beneficial results for subjects suffering from a disease or condition as described herein. The active drug substance may exhibit toxicity to cancer cells or have bactericidal or antiviral activity. Suitable active drug substances will depend on the disease or condition being treated and the tolerance of the subject to accept a specific active drug substance. Suitable active drug substances described herein may be administered, regardless of whether the active drug substance is hydrophilic, lipophilic, or amphiphilic. The active drug substance may be poorly soluble or highly soluble in an aqueous environment, or exhibit low or high systemic permeability (e.g., any BCS class I, class II, class III, or class IV drug). In addition, the active drug substance described herein may also include any protein drug, such as an antibody (e.g., a humanized antibody).
[0162] Exemplary active drug substances can include small molecules. In some aspects, small molecules can have a molecular weight of about 50 g / mol to about 1,000 g / mol (i.e. ≈50 Da-1,000 Da), including each integer in a specified range. In some aspects, small molecules can have a molecular weight of about 50 g / mol, about 100 g / mol, about 150 g / mol, about 200 g / mol, about 250 g / mol, about 300 g / mol, about 350 g / mol, about 400 g / mol, about 450 g / mol, about 500 g / mol, about 550 g / mol, about 600 g / mol, about 650 g / mol, about 700 g / mol, about 750 g / mol, about 800 g / mol, about 850 g / mol, about 900 g / mol, about 950 g / mol or about 1000 g / mol.
[0163] Other suitable active drug substances can include larger compounds or proteins. In some aspects, the compound or protein can have an atomic mass of about 1 kDa to about 250 kDa, including each integer in the specified range. In some aspects, the compound or protein can have an atomic mass of about 1 kDa, about 5 kDa, about 10 kDa, about 15 kDa, about 20 kDa, about 25 kDa, about 50 kDa, about 75 kDa, about 100 kDa, about 125 kDa, about 150 kDa, about 175 kDa, about 200 kDa, about 225 kDa, or about 250 kDa.
[0164] In some embodiments described herein are methods for administering one or more bioactive agents to an animal, preferably a mammal, most preferably a human, for the prevention, treatment or amelioration of one or more symptoms associated with a disease, disorder or infection by delivering the one or more bioactive agents to the subject's skin. The methods described herein can be used to treat or prevent diseases or disorders of the lymphatic system, primary or metastatic neoplastic diseases (i.e., cancer). The bioactive agents can be provided in a pharmaceutically acceptable composition or formulation as known in the art or as described herein.
[0165] In some embodiments described herein, one or more bioactivators are present in liquid carriers as substantially dissolved solutions, suspensions or colloidal suspensions. Any suitable liquid carrier solution that at least meets the specification of the United States Pharmacopoeia (USP) can be used, and the tension of such solutions can be modified as known, referring to, for example, Remington:The Science and Practice of Pharmacy (Lloyd V.Allen Jr. compiles, the 22nd edition 2012. Exemplary non-limiting liquid carrier solutions can be aqueous, semi-aqueous or non-aqueous, depending on the bioactivator used. For example, aqueous liquid carriers can include any one or its combination in water and water miscible vehicle ethanol, liquid (low molecular weight) polyethylene glycol, etc. Non-aqueous carriers can include fixed oils, such as corn oil, cottonseed oil, peanut oil or sesame oil, etc. Suitable liquid carrier solutions can also include any one of the following items: preservative, antioxidant, complexing enhancer, buffer, acidulant, saline, electrolyte, viscosity enhancer, viscosity reducer, alkalizer, antimicrobial, antifungal, solubility enhancer or its combination.
[0166] Some embodiments described herein include methods for treating, preventing, reducing the likelihood of, improving or controlling a disease or condition in a subject in need, comprising administering a therapeutically effective dose or a prophylactic effective dose of one or more bioactive agents (e.g., active drug substances) to a subject, to the skin of a subject in need. In some aspects described herein, a method for treating, preventing cancer (e.g., treating one or more susceptible tumors or their metastatic disease), reducing the likelihood of, improving or controlling the cancer in a subject, comprising administering a therapeutically effective dose or a prophylactic effective dose of one or more bioactive agents (e.g., active drug substances) to a subject, to the skin of a subject in need. In some aspects, a method for treating or preventing a disease in a subject by delivering one or more bioactive agents to the skin of a subject is more effective than conventional delivery routes such as iv, sc, im or id injections.
[0167] In some embodiments described herein, the method for controlled delivery described herein causes one or more active drug substances to be deposited in one or more susceptible tumors. In some aspects, the concentration of one or more active drug substances delivered to one or more susceptible tumors is about 0.5% to about 75% of the initial dosage, including each integer within the specified range. The percentage of the agent delivered to one or more tumors can be evaluated by a combination of non-invasive techniques such as PET or SPECT or these techniques with XCT or MRJ as described herein. The initial dosage percentage of one or more agents delivered to one or more tumors herein can be quantified in the following manner: directly label one or more agents with a detectable radioactive marker, and then administer the agent using the method described herein. Standard positron emission tomography (PET) or single photon emission computed tomography (SPECT) or a combination of these techniques with X-ray computed tomography (CT) or magnetic resonance imaging (MRI) can be used to evaluate the imaging and quantification of radiolabeled agents. See, e.g., Ding and Wu., Theranostics, 2(11), 1040-20, 1053 (2012), which is incorporated herein by reference for its teachings herein. Useful radiolabels may include short-lived or long-lived isotopes such as, but not limited to, 11 C. 15 O. 18 F. 68 Ga, 64 Cu, 76 Br, 89 Zr and 124 I. The radiolabel selected will depend on the agent being tested and the specific labeling scheme well known in the art. The initial dose absorption percentage delivered to the tumor tissue measured initially using PET or a combination of these techniques with X-ray computed tomography (CT) or a combination of these techniques with X-ray computed tomography (CT) or a combination of these techniques with X-ray computed tomography (CT) or a combination of these techniques with X-ray computed tomography (CT) or SPECT imaging can be calculated using standard radiopharmaceutical dosimetry and tissue density tables, see Bolch et al., J. Nucl. Med., 50 (3), 477 (2009), which is incorporated herein by reference for teachings herein.
[0168] In some aspects, the concentration of one or more active drug substances delivered to one or more susceptible tumors is about 0.5% to about 50% of the initial dose, including each integer in the specified range. In some aspects, the concentration of one or more active drug substances delivered to one or more susceptible tumors is about 0.5% to about 25% of the initial dose, including each integer in the specified range. In some aspects, the concentration of one or more active drug substances delivered to one or more susceptible tumors is about 0.5% to about 15% of the initial dose, including each integer in the specified range. In some aspects, the concentration of one or more active drug substances delivered to one or more susceptible tumors is about 0.5% to about 10% of the initial dose, including each integer in the specified range. In some aspects, the concentration of one or more active drug substances delivered to one or more susceptible tumors is about 0.5% to about 5% of the initial dose, including each integer in the specified range. In some aspects, the concentration of one or more active drug substances delivered to one or more susceptible tumors is about 0.5%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70% or about 75% of the initial dose.
[0169] The percentage of the drug delivered to one or more tumors can be assessed by non-invasive techniques such as PET or SPECT as described herein or a combination of these techniques with X-CT or MRI. The percentage of initial dose absorption delivered to tumor tissue measured initially using PET or SPECT imaging can be calculated using standard radiopharmaceutical dosimetry and tissue density tables (e.g., as described for delivery to lymphoid tissue).
[0170] Alternatively, to assess relative tumor drug concentrations, one or more tumors that have been treated or administered with one or more labeled (e.g., radiolabeled) agents as described herein can be harvested from a subject. To determine the biodistribution and percentage of the initial dose delivered per gram of tumor tissue, standard well-known techniques can be used to measure and quantify the specific radioactivity counts within the tissue and compare them to the radioactivity measurements of the initial dose.
[0171] In some embodiments described herein are methods for increasing the amount of a bioactive agent delivered to one or more susceptible tumors. In some aspects, because more bioactive agents are targeted to the tumor, there is less chance of harmful side effects while showing increased therapeutic efficacy. In some aspects, the amount of bioactive agent required to treat one or more susceptible tumors is about 1% to about 75% of the dose of the same bioactive agent required to treat one or susceptible tumors by conventional delivery routes, including each integer in the specified range; the conventional delivery routes are such as iv, sc, im or id injections. In some aspects, the amount of bioactive agent required to treat one or more susceptible tumors is about 1% to about 75% of the dose required to treat one or susceptible tumors by conventional delivery routes, including each integer in the specified range; the conventional delivery routes are such as iv, sc, im or id injections. In some aspects, the amount of bioactive agent required to treat one or more susceptible tumors is about 1% to about 50% of the dose required to treat one or susceptible tumors by conventional delivery routes, including each integer in the specified range; the conventional delivery routes are such as iv, sc, im or id injections. In some aspects, the amount of biologically active agent required to treat one or more susceptible tumors is about 1% to about 25%, including each integer in the specified range, of the dose required to treat one or susceptible tumors by conventional delivery routes; the conventional delivery routes are, for example, iv, sc, im, or id injections. In some aspects, the amount of biologically active agent required to treat one or more susceptible tumors is about 1% to about 10%, including each integer in the specified range, of the dose required to treat one or susceptible tumors by conventional delivery routes; the conventional delivery routes are, for example, iv, sc, im, or id injections. In some aspects, the amount of biologically active agent required to treat one or more susceptible tumors is about 1%, about 2%, about 3%, about 4%, about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70% or about 75% of the dose required to treat one or susceptible tumors by conventional delivery routes; such as iv, sc, im or id injection.
[0172] In some embodiments, the therapeutic efficacy of one or more bioactive agents delivered to one or more susceptible tumors as described herein can be measured as a reduction in tumor size, a reduction in tumor metastasis, an improvement in organ tissue function, a reduction in related side effects, a reduction in the need for surgical intervention, an improvement in quality of life, an increase in overall survival, and an increase in refractory-free survival, or a mixture or combination thereof.
[0173] In some embodiments, the method of targeted delivery of one or more bioactive agents to one or more susceptible tumors results in a greater reduction in size or a greater reduction in metastasis of one or more tumors compared to conventional delivery routes; the conventional delivery routes are, for example, iv, sc, im or id injections. In some aspects, the size of one or more tumors is reduced by about 5% to about 99% or more, including each integer within the specified range. In some aspects, the size of one or more tumors is reduced by about 5%, about 6%, about 7%, about 8%, about 9%, about 10%, about 15%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90% or about 95% or about 99% or more.
[0174] The reduction of tumor size and metastatic reduction (e.g., solid tumors) and the survival period without refractory disease can be evaluated and quantified by any common imaging method known in the art. For example, magnetic resonance imaging (MRI) or magnetic resonance spectroscopy (MRS) can be used to non-invasively track and monitor tumor size or tumor metastasis or invasiveness after administration of one or more bioactive agents. See, for example, Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Oncology (Jackson et al., 2013) and Gillies and Morse., Annu. Rev. Biomed Eng., 7, 287-326 (2005), each of which is incorporated herein by reference for the corresponding teachings of MRI and MRS.
[0175] In some aspects described herein, targeted delivery of one or more bioactive agents to one or more susceptible tumors results in reduced side effects. The reduction in side effects is due to the positioning of one or more bioactive agents within a tumor or tumor metastasis. In addition, as described herein, the reduction in the amount of bioactive agent required to cause the same therapeutic response (e.g., a reduction in tumor size or a reduction in metastatic potential) reduces the amount of potential side effects of any suitable delivery bioactive agent.
[0176] Thus, the methods described herein provide targeted delivery of one or more bioactive agents to one or more susceptible tumors in a subject by initial delivery to the skin using the methods described herein, resulting in previously unobtained beneficial therapeutic outcomes, including dose savings, increased drug efficacy, reduced side effects, reduced metastatic potential, reduced tumor-related inflammation, and prolonged survival of the subject. Thus, the methods described herein provide increased deposition of the therapeutic agent within one or more susceptible tumors when compared to iv, sc, im, or id injection methods. Any suitable cancer, tumor, or metastatic spread thereof can be treated by the methods described herein. Thus, the methods described herein provide treatment of a disease in a patient in need of treatment; the disease, for example, cancer, by improving the amount of the agent deposited within or near tumor tissue.
[0177] In some embodiments, the diffusion or movement of an applied agent through the epidermis can be increased by applying one or more permeation or penetration enhancers or contacting the subject's epidermis with one or more permeation or penetration enhancers. In some aspects, the permeation or penetration enhancer can be chemical, physical or electrical. Permeation enhancers are used to increase the movement or diffusion of one or more agents through the epidermal stratum corneum and into the viable epidermis. Permeation enhancers can further promote the movement or diffusion of one or more applied agents through the viable epidermis (including the basement membrane of the viable epidermis) and into the viable dermis below. See, for example, Prasunitz and Langer, Nature Biotechnol, 26 (11), 1261-1268 (2008), which is incorporated herein by reference for teaching of the use of epidermal permeation enhancers in transdermal drug delivery.
[0178] In some embodiments described herein, an effective amount of one or more chemical penetration enhancers can be delivered to the epidermis. Without being bound by any theory, it is believed that the chemical penetration enhancers described herein can promote the permeability of the stratum corneum to the applied agent by denaturing intracellular keratin, causing swelling due to hydration, affecting the cell desmosomes that maintain corneocyte adhesion, or changing the barrier of lipids within the lipid bilayer. Non-limiting examples of chemical penetration enhancers can include sulfoxides such as dimethyl sulfoxide and dodecyl methyl sulfoxide; urea; alcohols such as ethanol, octanol and propylene glycol, pyrrolidones and derivatives such as N-methyl-2-pyrrolidone and 2-pyrrolidone; azones and derivatives such as 1-dodecylazacycloheptan-2-one; dioxolane derivatives; anionic, cationic, nonionic or zwitterionic surfactants such as sodium dodecyl sulfate, hexadecyltrimethylammonium bromide, sorbitan monolaurate, polysorbate 80, dodecyldimethylaminopropyl sulfate; terpenes such as menthol or limonene; fatty acids such as oleic acid or undecanoic acid; or a hydrating amount of water.
[0179] In some embodiments described herein, physical penetration enhancers can be used to increase the permeability of the epidermis to the administered agent. In some aspects, physical penetration enhancers can rely on the use of sound, application of electric fields, or interaction with specific structures of the epidermis to increase the permeability of the epidermis. Non-limiting examples include sonophoresis (e.g., ultrasound), iontophoresis, electroporation, or nanostructure contact surfaces (e.g., nanotopography).
[0180] In some embodiments described herein, the method for initially controlling the delivery of one or more agents to the skin for targeted delivery to one or more tumors as described herein may include delivering one or more agents through a device comprising two or more delivery structures, the delivery structures being capable of penetrating the stratum corneum and achieving a delivery depth and volume in the skin, and controllably delivering the one or more agents at an administration rate as described herein. The delivery structures may be attached to a backing substrate of the delivery device and arranged at one or more different angles to penetrate the stratum corneum and deliver the one or more agents. In some aspects, the backing substrate comprising the delivery structure described herein may be in contact with the skin of the subject and may have a cylindrical, rectangular, or geometrically irregular shape. The backing substrate also includes a two-dimensional surface area. In some aspects, the two-dimensional surface area may be about 1 mm 2 To about 10,000mm 2 . In some aspects, the delivery structure can include any geometric shape (e.g., cylindrical, rectangular, or geometrically irregular). In addition, the delivery structure can include a length and a cross-sectional surface area. In some aspects, the delivery structure can have an overall length that is greater than the cross-sectional diameter or width. In some other aspects, the delivery structure can have a cross-sectional diameter or width that is greater than the overall length. In some aspects, the cross-sectional width of each delivery structure can be about 5 μm to about 140 μm, and the cross-sectional area can be about 25 μm 2 to about 15,000 μm 2 , including each integer within the specified range. In some aspects, the length of each delivery structure can be from about 10 μm to about 1,000 μm, including each integer within the specified range. Surface areas and cross-sectional surface areas as described herein can be determined using standard geometric calculations known in the art.
[0181] The delivery structures described herein need not be identical to each other. Devices with multiple delivery structures can each have different lengths, outer diameters, inner diameters, cross-sectional shapes, nanotopographic surfaces, and / or spacing between each delivery structure. For example, the delivery structures can be spaced apart in a uniform manner, such as in the form of a rectangular or square grid or concentric circles. The spacing can depend on many factors, including the height and width of the delivery structure, and the amount and type of the medicament intended to be delivered by the delivery structure. In some aspects, the spacing between each delivery structure can be from about 1 μm to about 800 μm, including each integer within the specified range.
[0182] In some embodiments, the delivery structure can include a needle array connected to a liquid carrier medium fluid comprising one or more medicaments. In some respects, the needle array can include 2 to 50,000 needles with a structural mechanism for controlling skin penetration and fluid delivery to the skin (e.g., penetrating and delivering to the skin), see, for example, US20150367117, which is incorporated herein by reference in its entirety. In some respects, the needle array can include a plurality of needles with a structural mechanism for controlling skin penetration and fluid delivery to the skin. In some other aspects, the needle array can also include a random or structured nano-topography manufactured on each needle. Needle or needle array can be attached to a larger drug delivery device, the device including a fluid delivery rate controller, an adhesive for attaching to the skin, a fluid pump, etc. If desired, the delivery rate of medicament can be variably controlled by a pressure generating mechanism. The delivery rate desired for epidermis as described herein can be triggered by driving one or more medicaments described herein using applied pressure or other driving mechanisms, and the other driving mechanisms include pumps, syringes, pens, elastomeric membranes, gas pressure, piezoelectric, electric, electromagnetic or osmotic pumps or use rate control membranes or combinations thereof. Specific exemplary structures and devices including mechanisms for controllably applying one or more medicaments to epidermis are described in US20110270221, US20120187814, US20130144217, US20130144257, US20130150822, US20130158505, US20130165861, US20140343532, US20150360018, US20150367117 and US20160106965, each of which is incorporated herein by reference in its entirety.
[0183] In some embodiments described herein, the delivery device can include a needle array in the form of a patch. In some aspects, the needle array is capable of penetrating the shallowest layer of the stratum corneum, and first delivering one or more agents as described herein to at least a portion or all of the non-viable epidermis, at least a portion or all of the viable epidermis and / or at least a portion of the viable dermis of the subject, and then delivering to one or more tumors. These needles can also include nanotopography in a random or organized pattern on the surface of the needle. In some aspects, the nanotopography pattern can display fractal geometry.
[0184] Exemplary and non-limiting devices and structures for delivering one or more pharmaceutical agents to the skin are shown in Figure 3 and Figure 4 In. Figure 3 As shown, the needle assembly as shown may include a support 42 having a top surface 44 and a bottom surface 46, and defining a plurality of holes 50 between the top surface 44 and the bottom surface 46. In addition, the needle assembly may also include a plurality of needles 48 extending outwardly from the bottom surface 46. As described above, each needle 48 may define one or more channels 56 in fluid communication with the hole 50. In this way, an active agent in a liquid carrier as described herein contained in a suitable reservoir can be guided from the top surface 44 of the support 42 through the hole 50 and into the needle 48 for subsequent delivery to the user's skin. The methods described herein provide delivery of one or more agents to the skin layer and ultimately to the susceptible lymphatic capillary plexus and / or capillary plexus.
[0185] The needles described above may also include nanotopography as described herein. Figure 4 The ends of two representative needles 22 are schematically shown. In this particular embodiment, the needles 22 define a central exit lumen 24, which can be used to deliver a drug through each needle 22 of a needle array as described herein. In some other embodiments, the needles can have multiple exit lumens for delivering a drug through the needles. The surface 25 of the needles 22 can define a nanotopography region 26. In this particular embodiment, the nanotopography 26 defines a random pattern of needles on the surface 25 of the needles 22; however, in some other embodiments, the nanotopography can be structured or in a partially structured / unstructured manner.
[0186] In some embodiments described herein, a delivery device including a needle array with a nanotopography as described herein acts as a penetration enhancer and can increase the delivery of one or more agents through the epidermis. As described herein, this delivery can occur by regulating a transcellular transport mechanism (e.g., an active or passive mechanism) or by paracellular permeation. Without being bound by any theory, a nanostructured or nanotopographic surface can increase the permeability of one or more layers (including the epidermal basement membrane) of a viable epidermis by modifying the cell / cell tight junctions that allow paracellular transport or modifying the cell active transport path (e.g., transcellular transport), thereby allowing the administered agent to diffuse or move and / or actively transport through the viable epidermis and enter the viable dermis of the lower layer. This effect may be due to the regulation of the gene expression of cell / cell tight junction proteins. As previously described, there are tight junctions in viable skin and particularly viable epidermis. The opening of tight junctions can provide a paracellular pathway to improve the delivery of any agent, such as those previously blocked for delivery through the skin.
[0187] In some embodiments described herein, a delivery device comprising a needle array having a nanotopography regulates the gene nucleic acid expression of a cell / cell contact gene of one or more viable epithelial cell types (e.g., viable epidermis, dermal skin cells, capillary cells, or capillary lymphatic cells). In some aspects, the nucleic acid gene expression of one or more cell / cell contact proteins is increased. In some aspects, the nucleic acid gene expression of one or more cell / cell contact proteins is reduced. Any method for measuring gene expression levels can be used, including but not limited to PCR, RT-PCR, qRT-PCR, microarrays, Northern blotting, RNA sequencing, etc.
[0188] The interaction between a single cell and the nano-morphology structure can increase the permeability of epithelial tissue (e.g., epidermis) and induce the passage of medicaments through barrier cells and promote transcellular transport. For example, the interaction with the keratinocytes of the viable epidermis can promote the distribution of medicaments into keratinocytes (e.g., transcellular transport), and then diffuse through the cells and pass through the lipid bilayer. In addition, the interaction of the nano-morphology structure with the keratinocytes of the stratum corneum can induce changes in barrier lipids or corneodesmosomes, thereby causing the medicament to diffuse through the stratum corneum into the viable epidermis layer of the lower layer. Although medicaments can pass through obstacles according to the paracellular pathway and the transcellular pathway, the main transport path can be changed according to the properties of the medicament.
[0189] In some embodiments described herein, a delivery device comprising a needle array having a nanotopography regulates protein expression of cell / cell contact genes of one or more viable epithelial cell types (e.g., viable epidermis, dermal skin cells, capillary cells, or capillary lymphatic cells). In some aspects, protein expression of one or more cell / cell contact proteins is increased. In some aspects, protein expression of one or more cell / cell contact proteins is reduced. Any method for measuring protein expression levels can be used, including but not limited to Western blotting, tissue imaging (e.g., fluorescence or chemiluminescence imaging), mass spectrometry, etc.
[0190] In some embodiments described herein, the device may interact with one or more components of epithelial tissue to increase the porosity of the tissue, making it susceptible to paracellular and / or transcellular transport mechanisms. Epithelial tissue is one of the main tissue types of the body. Epithelial tissue that can become more porous may include simple epithelium and stratified epithelium, including keratinized epithelium and transitional epithelium. In addition, the epithelial tissues covered herein may include any cell type of the epithelial layer, including but not limited to keratinocytes, endothelial cells, lymphatic endothelial cells, squamous cells, columnar cells, cubic cells and pseudostratified cells. Any method for measuring porosity can be used, including but not limited to any epithelial permeability assay. For example, overall permeability assays can be used to measure epithelial (e.g., skin) porosity or in vivo barrier function. In one embodiment, overall permeability assays use 5-bromo-4-chloro-3-indolyl-β, D-galactopyranoside (X-Gal). Unfixed, untreated samples are rinsed with phosphate buffered saline (PBS) and dried briefly. The samples are immersed in a standard X-Gal reaction mixture and the pH is adjusted to 4.5. After incubation at 37°C for 8-10 hours, the samples are washed with PBS for 1-2 minutes and analyzed. In one embodiment, the overall permeability is determined using a histological dye, such as, but not limited to, toluidine blue or hematoxylin. Unfixed, untreated samples are incubated in methanol for 1-5 minutes and rinsed in PBS. The samples are incubated in 0.5% hematoxylin or 0.1% toluidine blue and then embedded in agarose for analysis. In one embodiment, sample analysis is performed by photographing the prepared samples and evaluating based on the degree of dye penetration. Other methods known in the art may also be used. See, for example, Indra and Leid., Methods Mol Biol., (763) 73-81 (2012), which is incorporated herein by reference for teachings herein.
[0191] In some embodiments described herein, the structural changes caused by the presence of nanotopography surfaces on barrier cells are temporary and reversible. Surprisingly, it was found that the use of nanostructured nanotopography surfaces causes a temporary and completely reversible increase in the porosity of epithelial tissue by changing the connection stability and dynamics, without being bound by any theory, which can cause the administered agent to pass through the epidermis and enter the cell paracellular and transcellular transport in the viable dermis to temporarily increase. Therefore, in some aspects, after removing the nanotopography, the permeability of the epidermis or epithelial tissue caused by the nanotopography increases, such as the promotion of the cell paracellular or transcellular diffusion or movement of one or more agents is restored to the normal physiological state existing before the epithelial tissue is contacted with the nanotopography. In this way, the normal barrier function of barrier cells (e.g., epidermal cells) is restored and the further diffusion or movement of the molecules that occur will not exceed the normal physiological diffusion or movement of the molecules in the subject's tissue.
[0192] These reversible structural changes caused by the nanotopography may play a role in limiting secondary skin infections, absorbing harmful toxins, and limiting dermal irritation. In addition, the gradual reversal of epidermal permeability from the top layer of the epidermis to the basal layer may promote the downward movement of one or more agents through the epidermis and into the dermis, and prevent the reflux or reverse diffusion of one or more agents back into the epidermis.
[0193] In some alternative embodiments, methods for delivering one or more agents to the skin include not only needle-, microneedle-, or nanoneedle-based injections, but also other delivery methods such as needle-less or needle-free ballistic injection of fluids, iontophoresis, and direct deposition of fluids, solids, or other dosage forms into the skin epidermis.
[0194] In some embodiments described herein, a device having at least 2 or more delivery structures is applied to the skin surface of a subject to treat a disease or condition described herein. In some aspects, the device is applied to a region of the subject's skin, wherein the location of the skin on the body is dense with lymphatic capillaries and / or capillaries. Multiple devices can be applied to one or more locations of the skin with a dense network of lymphatic capillaries. In some aspects, 1, 2, 3, 4, 5 or more devices can be applied. These devices can be separated from each other in space or applied very close or juxtaposed. Exemplary and non-limiting locations densely with lymphatic vessels include the palmar surface of the hand, the scrotum, the sole of the foot, and the lower abdomen.
[0195] It will be readily apparent to those skilled in the art that suitable modifications and adjustments to the compositions, methods and applications described herein can be made without departing from the scope of any embodiment or aspect thereof. The compositions and methods provided by the invention are exemplary and are not intended to limit the scope of the specified embodiments. All of the various embodiments, aspects and options disclosed herein can be combined in all variant forms. The scope of the compositions, formulations, methods and processes described herein includes all actual or potential combinations of the embodiments, aspects, options, examples and preferred requirements described herein. All patents and publications described herein are incorporated herein by reference for their specific teachings.
[0196] Example 1. Skin image
[0197] Figure 1 The overall structure of the skin including dermis and epidermis is shown in Figure 3. The dermis is composed of countless tissue types, and generally shows a total thickness of about 500 μm to about 4000 μm. It is often found that lymphatic capillaries and capillaries exist together as shown in the figure, or they can exist as a separate entity. As shown in the figure, capillaries and lymphatic capillaries are often located in the top of the dermis (for example, near the epidermis dermis or epidermal basement membrane), in a part of the papillary dermis. Larger blood vessels (for example, blood vessels as shown in the figure) are usually found in the lower reticular dermis. Other tissue types important to dermal function include larger arteries, arterioles, sweat gland ducts, sebaceous glands, neuroplasts, connective tissue and extracellular matrix (extra cellular matricis), smooth muscle and hair follicles. What is located below the reticular dermis is the subcutaneous tissue layer, which is mainly composed of adipose tissue and generally does not contain any lymphatic vascular system or vascular system.
[0198] like Figure 2 As shown in A, the epithelial skin layer is formed by four major cell layers that lack many other tissue types of the dermis (e.g., blood capillaries and lymphatic capillaries, etc.), and generally ranges in thickness from about 20 μm to about 400 μm. As shown in the figure, from top to bottom is the basement membrane, followed by the basal layer or germinal layer, the squamous cell layer or stratum spinosum (spinous layer), the granular cell layer or granular layer, and the stratum corneum or corneum. The epidermis is in principle non-mitotic, and the stratum corneum contains non-viable enucleated barrier-providing cells; however, as Figure 2 The basal layer shown in B is composed of symmetrically dividing stem cells and other transiently proliferating cells for keratin regeneration.
[0199] Example 2. Depth of penetration into the skin
[0200] Needle arrays were fabricated on patches and used to estimate the average range of drug delivery depths within adult guinea pig skin. Figure 5 As shown, the methylene blue dye was applied to an average depth of about 92 μm, which confirmed a depth distribution range of about 5 μm to about 200 μm (Gaussian distribution of depth). Figure 6 As shown, the structure and depth in the skin can be estimated by using optical coherence tomography. By observing various horizontal slices of the skin, the skin structure after the needle series is applied can be visualized.
[0201] Example 3. Regulation of epidermal tight junction proteins
[0202] Pin arrays with nano-topography surfaces were manufactured on patches and tested on in vitro monolayers of Caco-2 epithelial cells. As shown in Figure 7A, ZO-1 tight junction proteins show normal staining patterns. However, when the pin arrays with nano-pattern surfaces are placed near Caco-2 cells, disturbed staining patterns can be observed. This wrinkled pattern shows that the connection in the area where the nano-topography is located is remodeled (Figure 7B). When the pin arrays with nano-topography are removed, the staining pattern returns to normal, which shows the spatial and temporal effects on tight junction proteins such as ZO-1 (Figure 7C).
[0203] Example 4. Trastuzumab Better delivery to tumors in vivo
[0204] The ability of trastuzumab (anticancer drug) to be delivered to tumors by application to the skin was tested in a mouse xenograft tumor model. Xenograft tumors were generated in mice using the HER-2 positive JIMT-1 human breast cancer cell line. A needle array with a nanotopography surface was made on the patch and applied to the dorsal side of the mouse presenting the tumor. Then different amounts of trastuzumab were applied to the skin of these mice at different application rates, and the concentration of trastuzumab in the tumor was evaluated. As shown in the figure Figure 8 , administration of 0.22 mg trastuzumab at a rate of 100 μl / h produced higher concentrations of trastuzumab in JIMT-1 tumors compared to an approximately 10-fold greater intravenously administered trastuzumab dose (2 mg iv).
[0205] When compared to even higher doses of intravenously administered trastuzumab ( FIGS. 9A-B ), trastuzumab administered to the skin demonstrated greater or comparable efficacy in treating tumors, as evidenced by extensive areas of tumor necrosis (black arrows point to necrotic tissue portions).
[0206] Example 5. Optimal drug delivery to tumors in vitro
[0207] Tested the efficiency of drug delivery directly in tumors grown in vitro using needle arrays with nano-topography surfaces.Tumor tissue grows in vitro and anticancer drugs are applied to the tumor tissue by adding drugs to tissue culture medium or using needle arrays.The distribution of drugs is evaluated by frozen section technology and subsequent tissue visualization (Figures 10A and 10B).The impact on cancer cell proliferation is measured using standard proliferation assay staining techniques after drug delivery.As shown in Figure 10A, simply adding drugs to culture medium causes little drug absorption in the whole tumor, and most of them are retained in the surface layer of the cell (as shown in brackets).By contrast, as shown in Figure 10B, drugs are applied to tumors with needle arrays to show higher distribution levels in the whole tumor tissue sections, and almost no drugs are retained on the surface (as shown in black arrows).Compared with the direct application (Figure 10D; the example of proliferating cells indicated by arrows) using needle arrays, the drugs supplemented only with tissue culture medium have a reduced antiproliferative effect (Figure 10C).
[0208] Example 6. Effect of Etanercept ( In vivo imaging of lymphatic delivery of anti-inflammatory drugs to the lymphatic vasculature and biodistribution in rats
[0209] The ability to deliver the protein therapeutic etanercept directly to the lymphatic system by application to the skin was tested. As previously described, etanercept was fluorescently labeled using near-infrared light for in vivo visualization, see Sevick-Muraca et al., J. Clin Invest., 124(3), 905-914 (2014), which is incorporated herein by reference for its teachings herein. Etanercept was administered to the skin of rats by placing a delivery device comprising a needle array on the dorsal side of the rats. Fig.11 and Fig.12 As shown in , administration of etanercept to the skin results in uptake by the lymphatic vasculature and subsequent distribution to primary and secondary lymph node tissues.
[0210] The biodistribution of etanercept after delivery was studied on a variety of tissue types. Thus, delivery of etanercept to the skin resulted in much higher levels in the axillary and inguinal lymph nodes when compared to traditional iv, sc, or id approaches ( Fig.13 ).
[0211] Example 7. Serum absorption rate of etanercept after delivery to the skin
[0212] like Fig.14 As shown, the rate of serum absorption of etanercept after application to the skin was about the same as that of iv, sc or id methods.
Claims
1. Use of one or more biologically active agents for treating a disease comprising one or more tumors, wherein the treatment comprises administering the one or more biologically active agents to the one or more tumors, characterized in that The administration includes: (a) applying one or more delivery devices having 2 to 50,000 delivery structures to one or more sites of the skin including the vascular system or lymphatic system, wherein the delivery device contacts one or more layers of the epidermis with one or more reversible permeation enhancers, the one or more reversible permeation enhancers comprising inducing a reversible increase in the permeability of one or more barrier cells of the epidermis to at least the one or more pharmaceutical agents, wherein the one or more reversible permeation enhancers are one or more physical permeation enhancers, the one or more physical permeation enhancers comprising a nanostructured or nanotopographic surface; (b) administering a total liquid dosage of the one or more biologically active agents in a range of 2 to 50,000 sub-doses at a controlled administration flow rate via the delivery device; wherein each sub-dose of the one or more agents is independently administered to a plurality of separate depths within the epidermis prior to any subsequent diffusion or migration of the one or more biologically active agents within the epidermis, and wherein following the administering step, the one or more biologically active agents migrate or diffuse deeper through the epidermis to the basal layer of the epidermis and into at least a portion of the underlying viable dermis to effect uptake of a portion of the one or more biologically active agents by one or more susceptible capillary plexuses or lymphatic capillary plexuses; wherein following administration and uptake, the one or more bioactive agents circulate to the one or more tumors via the vascular system or lymphatic system; and wherein a higher concentration of the one or more biologically active agents is delivered to the one or more tumors compared to intravenous, intradermal, or subcutaneous delivery of the same one or more biologically active agents.
2. The use according to claim 1, characterized in that The epidermis includes a non-vital epidermis and a vital epidermis.
3. The use according to any one of claims 1-2, characterized in that Applying the total liquid dosage of the one or more bioactive agents to a plurality of depths within the epidermis includes applying to a depth of at least a portion of the non-viable epidermis and / or at least a portion of the viable epidermis.
4. The use according to any one of claims 1 to 3, characterized in that The plurality of depths range from about 1 μm to about 500 μm beyond the superficialmost surface layer of the epidermis of the subject.
5. The use according to claim 1, characterized in that: The total liquid dosage of the one or more bioactive agents is applied to multiple depths within the epidermis including one or more viable epidermis layers only and no non-viable epidermis layers, preferably from about 1 μm to about 250 μm beyond the deepest non-viable epidermis layer, but still within the viable epidermis.
6. The use according to any one of claims 1 to 5, characterized in that The average of the individual plurality of depths exhibits a combined average subdose delivery depth within the epidermis of about 70 μm to about 175 μm beyond the superficialmost layer of the epidermis.
7. The use according to any one of claims 1 to 6, characterized in that The plurality of separate depths have a combined average depth of application within the epidermis, wherein each separately applied sub-dose is at a deeper, shallower, or the same depth within the epidermis.
8. The use according to any one of claims 1 to 7, characterized in that The frequency of each individual sub-dose application depth within the viable and / or non-viable epidermis exhibits a Gaussian distribution of depths.
9. The use according to any one of claims 1 to 8, characterized in that The delivery device comprises an array comprising from 2 to 50,000 of the delivery structures in fluid communication with the one or more bioactive agents in a liquid carrier vehicle, wherein said delivery device comprises a mechanism for controlling said administration flow rate; wherein the delivery structure comprises means for penetrating at least the superficial layer of the epidermis; and wherein the one or more bioactive agents in a liquid carrier vehicle are delivered to the plurality of depths within the viable epidermis of a subject via the delivery structure, thereby administering 2 to 50,000 sub-doses of the one or more bioactive agents, preferably wherein the delivery structure comprises a standard or non-standard geometry; and / or Wherein the delivery structure comprises a needle.
10. The use according to any one of claims 1 to 9, characterized in that The one or more bioactive agents are administered at a controlled administration flow rate of about 0.01 μl / h to about 100 μl / h per delivery structure; and / or The overall controlled administration flow rate of the one or more bioactive agents to the multiple depths within the epidermis is about 0.02 μl / h / cm based on the total surface area of the delivery device in contact with the skin of the subject. 2 to about 50,000 μl / h / cm 2 ; and / or The one or more bioactive agents are delivered to the approximately 0.7 mm thick portion of the epidermis containing the one or more bioactive agents, prior to any subsequent diffusion or migration of the one or more bioactive agents within the epidermis. 3 To about 2,500mm 3 tissue volume; and / or wherein the one or more biologically active agents are continuously administered to the subject for a period of about 0.1 hours to about 96 hours.
11. The use according to any one of claims 1 to 10, characterized in that The nanotopographic surface is manufactured on the surface of the delivery structure according to any of claim 9.
12. The use according to any one of claims 1 to 11, characterized in that Administration of one or more bioactive agents achieves a dermal interstitial fluid pressure of about 1 mmHg to about 15 mmHg in the underlying dermis beneath the site of administration.
13. The use according to any one of claims 1 to 12, characterized in that The bioactive agents can be used to treat symptoms of a disease; slow the progression of the symptoms; delay the onset of the symptoms; prevent, ameliorate or alleviate the symptoms in a patient in need of treatment.
14. A delivery device for delivering one or more bioactive agents to one or more susceptible tumors of a subject, characterized in that: The delivery device comprises: an array comprising from 2 to 50,000 delivery structures in fluid communication with the one or more pharmaceutical agents in a liquid carrier vehicle, wherein the delivery device includes a mechanism for controlling the flow rate of administration; wherein the delivery structure comprises means for penetrating at least the superficial layer of the epidermis; wherein the one or more pharmaceutical agents in the liquid carrier vehicle are delivered by the delivery structure to multiple depths within the viable epidermis of the subject, thereby administering 2 to 50,000 sub-doses of the one or more pharmaceutical agents.
15. Use of one or more agents for delivery to one or more tumors of a subject, characterized in that The administration includes: (a) applying one or more delivery devices having 2 to 50,000 delivery structures to one or more sites of the skin including the vascular system or lymphatic system, wherein the one or more delivery devices contact one or more layers of the epidermis with one or more reversible permeation enhancers, the one or more reversible permeation enhancers comprising a chemical, physical or electrical permeation enhancer that induces a reversible increase in the permeability of one or more barrier cells of the epidermis to at least the one or more pharmaceutical agents; (b) administering a total liquid dosage of the one or more pharmaceutical agents in 2 to 50,000 sub-doses under the following conditions: at a controlled administration flow rate of about 0.01 μl / h to about 100 μl / h per delivery structure, at a total surface area of about 0.02 μl / h / cm2 in contact with the skin of the subject based on the one or more delivery devices; 2 to about 50,000 μl / h / cm 2 Total combined controlled application flow rate, wherein each sub-dose of the one or more agents is independently administered to a plurality of independent depths ranging from about 1 μm to about 500 μm beyond the shallowest surface layer of the epidermis of the subject, but still within the epidermis of the subject, prior to any subsequent diffusion or migration of the one or more agents within the epidermis, exhibiting a Gaussian distribution of delivery depths within the epidermis; and wherein after the administering step, the one or more agents diffuse deeper through the epidermis to the basal layer of the epidermis and into at least a portion of the underlying viable dermis to effect uptake of a portion of the one or more bioactive agents by one or more susceptible capillary plexuses or lymphatic capillary plexuses; and wherein following administration, the permeability of the one or more barrier cells is restored to the state prior to contacting the epidermis with the one or more permeability enhancers.
